Author: "Poenou G" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Poenou G"' showing total 76 results

Start Over Author "Poenou G"

76 results on '"Poenou G"'

1. Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives

Author: Poenou G, Dumitru Dumitru T, Lafaie L, Mismetti V, Heestermans M, and Bertoletti L
Subjects: fxi inhibitor- venous thromboembolic events- thromboprophylaxis- anticoagulant-clinical trials, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Geraldine Poenou,1 Teona Dimitru Dimitru,1– 3 Ludovic Lafaie,4,5 Valentine Mismetti,5,6 Marco Heestermans,5,7 Laurent Bertoletti1,5,8 1Therapeutic and Vascular Medicine Department, University Hospital of Saint Etienne, Saint Etienne, France; 2Internal Medicine Department, University Hospital Santa Lucía, Cartagena, Murcia, Spain; 3Catholic University San Antonio, Murcia, Spain; 4Geriatric Department, University Hospital of Saint Etienne, Saint Etienne, France; 5INSERM, UMR1059, Haemostasis and Vascular Dysfunction Team, Jean Monnet University, Saint-Etienne, F-42055, France; 6Pneumology Department, University Hospital of Saint Etienne, Saint Etienne, France; 7Auvergne-Rhône-Alpes French Blood Donation Agency, Saint-Etienne, F-42100, France; 8INSERM, CIC-1408, University Hospital of Saint Etienne, Saint Etienne, FranceCorrespondence: Laurent Bertoletti, Therapeutic and Vascular Medicine Department, University Hospital of Saint Etienne, Saint Etienne, France, Tel +33477827771, Fax +33477820482, Email Laurent.bertoletti@gmail.comAbstract: During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically improved the prevention of thrombosis. However, several unmet needs prevail in the field of thrombosis prevention, even in the DOACs’ era. The use of DOACs is still constrained and the drugs cannot be administered in every clinical scenario, such as an increased anticoagulant-associated bleeding risk, particularly in some specific populations (cancer – notably those with gastrointestinal or genitourinary cancer – and frail patients), the impossibility to be used in certain patients (eg, end-stage kidney failure during hemodialysis, pregnancy and breastfeeding), and their lack of efficacy in certain clinical scenarios (eg, mechanical heart valves, triple-positive antiphospholipid syndrome). Efforts to find a factor that upon antagonization prevents thrombosis but spares haemostasis have resulted in the identification of coagulation factor XI (FXI) as a therapeutic target. After briefly recapitulating the role of factor XI in the balance of haemostasis, we propose a narrative review of the key data published to date with compounds targeting factor XI to prevent thrombosis as well as the main ongoing clinical studies, opening up prospects for improving the care of patients requiring thrombosis prevention.Keywords: FXI inhibitor, venous thromboembolic events, thromboprophylaxis, anticoagulant, clinical trials
Published: 2022

2. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

Author: Adarraga, M.D., Alberich-Conesa, A., Amado, C., Amorós, S., Arcelus, J.I., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Blanco-Molina, A., Botella, E., Carrero, R., Casado, I., Criado, J., del Toro, J., De Ancos, C., De Juana-Izquierdo, C., Demelo-Rodríguez, P., Díaz-Brasero, A.M., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Dubois-Silva, A., Escribano, J.C., Espósito, F., Falgá, C., Farfán-Sedano, A.I., Fernández-Capitán, C., Fernández-Jiménez, B., Fernández-Muixi, J., Fernández-Reyes, J.L., Font, C., Francisco, I., Galeano-Valle, F., García, M.A., García de Herreros, M., García-Bragado, F., García-Ortega, A., Gavín-Sebastián, O., Gil-Díaz, A., Gil-Hernández, A., Gómez-Cuervo, C., Gómez-Mosquera, A.M., González-Martínez, J., Grau, E., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Jou, I., Joya, M.D., Lacruz, B., Lalueza, A., Lainez-Justo, S., Lecumberri, R., León-Ramírez, J.M., Lobo, J.L., López-De la Fuente, M., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Ruiz, A., López-Sáez, J.B., Lorente, M.A., Lorenzo, A., Lumbierres, M., Madridano, O., Maestre, A., Mas-Maresma, L., Marcos, M., Martín-Guerra, J.M., Martín-Martos, F., Mellado, M., Mena, E., Mercado, M.I., Moisés, J., Monreal, M., Muñoz-Blanco, A., Muñoz-Gamito, G., Nieto, J.A., Núñez-Fernández, M.J., Osorio, J., Otalora, S., Pacheco-Gómez, N., Paredes-Ruiz, D., Parra, P., Pedrajas, J.M., Pérez-Ductor, C., Pérez-Jacoiste, A., Pérez-Pérez, J.L., Peris, M.L., Pesce, M.L., Porras, J.A., Poyo-Molina, J., Puchades, R., Riera-Mestre, A., Rivera-Civico, F., Rivera-Gallego, A., Roca, M., Rubio, C.M., Rosa, V., Rodríguez-Cobo, A., Ruiz-Giménez, N., Ruiz-Ruiz, J., Salgueiro, G., Sancho, T., Sendín, V., Sigüenza, P., Soler, S., Suriñach, J.M., Tiberio, G., Tolosa, C., Torres, M.I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Varona, J.F., Vela, J.R., Vela, L., Vidal, G., Villalobos, A., Villares, P., Ay, C., Nopp, S., Pabinger, I., Engelen, M., Martens, C., Verhamme, P., Yoo, H.H.B., Arguello, J.D., Montenegro, A.C., Roa, J., Hirmerova, J., Malý, R., Accassat, S., Bertoletti, L., Bura-Riviere, A., Catella, J., Chopard, R., Couturaud, F., Espitia, O., Grange, C., Leclercq, B., Le Mao, R., Mahé, I., Moustafa, F., Plaisance, L., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Versini, E., Schellong, S., Braester, A., Brenner, B., Kenet, G., Najib, D., Tzoran, I., Farrashi, M., Sadeghipour, P., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., Dentali, F., Di Micco, P., Grandone, E., Imbalzano, E., Merla, S., Pesavento, R., Prandoni, P., Scarinzi, P., Siniscalchi, C., Taflaj, B., Tufano, A., Visonà, A., Vo Hong, N., Zalunardo, B., Fonseca, S., Manuel, M., Meireles, J., Bosevski, M., Eftimova, A., Zdraveska, M., Bounameaux, H., Mazzolai, L., Aujayeb, A., Caprini, J.A., Weinberg, I., Bui, H.M., Demelo-Rodriguez, Pablo, Alonso-Beato, Rubén, Jara-Palomares, Luis, Galeano-Valle, Francisco, Bura-Riviere, Alessandra, Visonà, Adriana, Francisco, Iria, Vidal, Gemma, López-Ruiz, Antonio, and Monreal, Manuel
Published: 2023
Full Text: View/download PDF

3. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

Author: Monreal, Manuel, Prandoni, Paolo, Brenner, Benjamin, Farge-Bancel, Dominique, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Verhamme, Peter, Caprini, Joseph A., Bui, Hanh My, Adarraga, M.D., Alberich-Conesa, A., Alonso-Carrillo, J., Amado, C., Amorós, S., Arcelus, J.I., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Blanco-Molina, A., Botella, E., Casado, I., Chasco, L., Cerdà, P., Criado, J., del Toro, J., De Juana-Izquierdo, C., Demelo-Rodríguez, P., Díaz-Brasero, A.M., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Dubois-Silva, A., Escribano, J.C., Espósito, F., Falgá, C., Fernández-Capitán, C., Fernández-Jiménez, B., Fernández-Muixi, J., Fernández-Reyes, J.L., Fidalgo, M.A., Font, C., Francisco, I., Galeano-Valle, F., García, M.A., García de Herreros, M., García-Bragado, F., García-Ortega, A., Gavín-Sebastián, O., Gil-Díaz, A., Gómez-Cuervo, C., Gómez-Mosquera, A.M., González-Martínez, J., González-Moreno, M., Grau, E., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Jaras, M.J., Jiménez, D., Jou, I., Joya, M.D., Lacruz, B., Lainez-Justo, S., Lalueza, A., Latorre, A., Lecumberri, R., Lobo, J.L., López-De la Fuente, M., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Ruiz, A., López-Sáez, J.B., Lorenzo, A., Lumbierres, M., Madridano, O., Maestre, A., Marcos, M., Martín-Martos, F., Mellado, M., Mena, E., Mercado, M.I., Moisés, J., Monreal, M., Muñoz-Blanco, A., Muñoz-Gamito, G., Morales, M.V., Nieto, J.A., Noguera-Gras, E., Núñez-Fernández, M.J., Osorio, J., Otalora, S., Pacheco-Gómez, N., Paredes-Ruiz, D., Parra, P., Pedrajas, J.M., Pérez-Ductor, C., Pérez-Jacoiste, M.A., Pérez-Pérez, J.L., Peris, M.L., Porras, J.A., Poyo-Molina, J., Puchades, R., Riera-Mestre, A., Rivera-Civico, F., Rivera-Gallego, A., Roca, M., Rosa, V., Rodríguez-Cobo, A., Ruiz-Giménez, N., Salgueiro, G., Sancho, T., Sendín, V., Sigüenza, P., Soler, S., Suriñach, J.M., Tiberio, G., Torres, M.I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Varona, J.F., Vela, L., Vela, J.R., Villalobos, A., Villares, P., Ay, C., Nopp, S., Pabinger, I., Engelen, M.M., Martens, C., Verhamme, P., Yoo, H.H.B., Arguello, J.D., Montenegro, A.C., Roa, J., Hirmerova, J., Malý, R., Accassat, S., Bertoletti, L., Bura-Riviere, A., Catella, J., Chopard, R., Couturaud, F., Espitia, O., Leclercq, B., Le Mao, R., Mahé, I., Moustafa, F., Plaisance, L., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Versini, E., Schellong, S., Braester, A., Brenner, B., Kenet, G., Tzoran, I., Sadeghipour, P., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., De Angelis, A., Dentali, F., Di Micco, P., Grandone, E., Imbalzano, E., Merla, S., Pesavento, R., Prandoni, P., Scarinzi, P., Siniscalchi, C., Tufano, A., Visonà, A., Vo Hong, N., Zalunardo, B., Gibietis, V., Kigitovica, D., Skride, A., Fonseca, S., Manuel, M., Meireles, J., Bosevski, M., Bounameaux, H., Mazzolai, L., Aujayeb, A., Caprini, J.A., Weinberg, I., Bui, H.M., Cohen, Omri, Barg, Assaf A., Nowak-Göttl, Ulrike, Amado-Fernández, Cristina, Mazzolai, Lucia, Tiberio, Gregorio, Skride, Andris, Morales, María del Valle, and Kenet, Gili
Published: 2023
Full Text: View/download PDF

4. Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

Author: Goedegebuur, J., Abbel, D., Accassat, S., Achterberg, W.P., Akbari, A., Arfuch, V.M., Baddeley, E., Bax, J.J., Becker, D., Bergmeijer, B., Bertoletti, L., Blom, J.W., Calvetti, A., Cannegieter, S.C., Castro, L., Chavannes, N.H., Coma-Auli, N., Couffignal, C., Edwards, A., Edwards, M., Enggaard, H., Font, C., Gava, A., Geersing, G.J., Geijteman, E.C.T., Greenley, S., Gregory, C., Gussekloo, J., Hoffmann, I., Højen, A.A., van den Hout, W.B., Huisman, M.V., Jacobsen, S., Jagosh, J., Johnson, M.J., Jørgensen, L., Juffermans, C.C.M., Kempers, E.K., Konstantinides, S., Kroder, A.F., Kruip, M.J.H.A., Lafaie, L., Langendoen, J.W., Larsen, T.B., Lifford, K., van der Linden, Y.M., Mahé, I., Maiorana, L., Maraveyas, A., Martens, E.S.L., Mayeur, D., van Mens, T.E., Mohr, K., Mooijaart, S.P., Murtagh, F.E.M., Nelson, A., Nielsen, P.B., Ording, A.G., Ørskov, M., Pearson, M., Poenou, G., Portielje, J.E.A., Raczkiewicz, D., Rasmussen, K., Trinks-Roerdink, E., Schippers, I., Seddon, K., Sexton, K., Sivell, S., Skjøth, F., Søgaard, M., Szmit, S., Trompet, S., Vassal, P., Visser, C., van Vliet, L.M., Wilson, E., Klok, F.A., and Noble, S.I.R.
Published: 2023
Full Text: View/download PDF

5. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Author: Trujillo‐Santos, Javier, Farge‐Bancel, Dominique, Pedrajas, José María, Gómez‐Cuervo, Covadonga, Ballaz, Aitor, Braester, Andrei, Mahé, Isabelle, Villalobos, Aurora, Porras, José Antonio, Monreal, Manuel, Adarraga, MD, Aibar, J, Aibar, MA, Amado, C, Arcelus, JI, Asuero, A, Barba, R, Barbagelata, C, Barrón, M, Barrón‐Andrés, B, Blanco‐Molina, A, Botella, E, Camon, AM, Casado, I, Castro, J, Castro, M, Chasco, L, Criado, J, de Ancos, C, del Toro, J, Demelo‐Rodríguez, P, Díaz‐Brasero, AM, Díaz‐Peromingo, JA, Di Campli, MV, Dubois‐Silva, A, Escribano, JC, Espósito, F, Falgá, C, Farfán‐Sedano, AI, Fernández‐Capitán, C, Fernández‐Reyes, JL, Fidalgo, MA, Flores, K, Font, C, Font, L, Francisco, I, Gabara, C, Galeano‐Valle, F, García, MA, García‐Bragado, F, García de Herreros, M, García de la Garza, R, García‐Díaz, C, García‐Hernáez, R, García‐Raso, A, Gil‐Díaz, A, Giménez‐Suau, M, Grau, E, Guirado, L, Gutiérrez, J, Hernández‐Blasco, L, Hernando, E, Jara‐Palomares, L, Jaras, MJ, Jiménez, D, Jiménez, R, Jiménez‐Alfaro, C, Joya, MD, Lainez‐Justo, S, Latorre, A, Lima, J, Llamas, P, Lobo, JL, López‐Jiménez, L, López‐Miguel, P, López‐Núñez, JJ, López‐Reyes, R, López‐Sáez, JB, Lorenzo, A, Madridano, O, Maestre, A, Marchena, PJ, Martín‐Martos, F, Martínez‐Urbistondo, D, Mella, C, Mercado, MI, Moisés, J, Morales, MV, Muñoz‐Blanco, A, Muñoz‐Rivas, N, Navas, MS, Nieto, JA, Nofuentes‐Pérez, E, Núñez‐Fernández, MJ, Obispo, B, Olid, M, Olivares, MC, Orcastegui, JL, Osorio, J, Otalora, S, Otero, R, Paredes, D, Parra, P, Pellejero, G, Portillo, J, Rivera‐Civico, F, Rodríguez‐Chiaradía, DA, Rodríguez‐Matute, C, Rogado, J, Rosa, V, Ruiz‐Artacho, P, Ruiz‐Giménez, N, Ruiz‐Ruiz, J, Ruiz‐Sada, P, Salgueiro, G, Sánchez‐Martínez, R, Sánchez‐Muñoz‐Torrero, JF, Sancho, T, Soler, S, Suárez‐Rodríguez, B, Suriñach, JM, Tirado, R, Torres, MI, Tolosa, C, Uresandi, F, Valero, B, Valle, R, Varona, JF, Vidal, G, Villares, P, Zamora, C, Engelen, M, Vanassche, T, Verhamme, P, Hirmerova, J, Malý, R, Ait Abdallah, N, Bertoletti, L, Bura‐Riviere, A, Catella, J, Couturaud, F, Crichi, B, Debourdeau, P, Espitia, O, Falvo, N, Helfer, H, Lacut, K, Le Mao, R, Moustafa, F, Poenou, G, Quere, I, Schellong, S, Brenner, B, Tzoran, I, Nikandish, R, Bilora, F, Brandolin, B, Ciammaichella, M, Di Micco, P, Imbalzano, E, Maida, R, Pace, F, Pesavento, R, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tufano, A, Visonà, A, Zalunardo, B, Birzulis, J, Skride, A, Zaicenko, A, Fonseca, S, Martins, F, Meireles, J, Bosevski, M, Bounameaux, H, Mazzolai, L, Ochoa‐Chaar, CI, Weinberg, I, and Bui, HM
Published: 2022
Full Text: View/download PDF

6. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

Author: Monreal, Manuel, Prandoni, Paolo, Brenner, Benjamin, Farge-Bancel, Dominique, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Verhamme, Peter, Caprini, Joseph A., Bui, Hanh My, Adarraga, M.D., Aibar, J., Aibar, M.A., Alonso, J., Amado, C., Arcelus, J.I., Asuero, A., Azcarate-Agüero, P., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Blanco-Molina, A., Beddar Chaib, F., Camon, A.M., Castro, J., Chasco, L., Criado, J., de Ancos, C., del Toro, J., Demelo-Rodríguez, P., Díaz-Brasero, A.M., Díaz-Pedroche, M.C., Díaz-Peromingo, J.A., Di Campli, M.V., Dubois-Silva, A., Escribano, J.C., Espósito, F., Farfán-Sedano, A.I., Fernández-Capitán, C., Fernández-Reyes, J.L., Fidalgo, M.A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., García, M.A., García-Bragado, F., García de Herreros, M., García de la Garza, R., García-Díaz, C., Gil-Díaz, A., Gómez-Cuervo, C., Giménez-Suau, M., Grau, E., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Jiménez-Alfaro, C., Joya, M.D., Lainez-Justo, S., Latorre, A., Lima, J., Lobo, J.L., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Sáez, J.B., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P.J., Martín del Pozo, M., Martín-Martos, F., Martínez-Urbistondo, D., Mella, C., Mercado, M.I., Moisés, J., Monreal, M., Muñoz, M., Muñoz-Blanco, A., Nieto, J.A., Nofuentes-Pérez, E., Núñez-Fernández, M.J., Olid-Velilla, M., Olivares, M.C., Osorio, J., Otalora, S., Otero, R., Pedrajas, J.M., Pellejero, G., Porras, J.A., Portillo, J., Rodríguez-Matute, C., Rosa, V., Ruiz-Artacho, P., Ruiz-Ruiz, J., Salgueiro, G., Sánchez-Martínez, R., Sánchez-Muñoz-Torrero, J.F., Sancho, T., Soler, S., Suárez-Rodríguez, B., Suriñach, J.M., Torres, M.I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Varona, J.F., Vela, L., Vela, J.R., Vidal, G., Villalobos, A., Villares, P., Zamora, C., Ay, C., Nopp, S., Pabinger, I., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Malý, R., Accassat, S., Ait Abdallah, N., Bertoletti, L., Bura-Riviere, A., Catella, J., Couturaud, F., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Grange, C., Helfer, H., Lacut, K., Le Mao, R., Mahé, I., Morange, P., Moustafa, F., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Quere, I., Schellong, S., Braester, A., Brenner, B., Kenet, G., Tzoran, I., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., De Angelis, A., Di Micco, P., Imbalzano, E., Merla, S., Pesavento, R., Prandoni, P., Siniscalchi, C., Tufano, A., Visonà, A., Vo Hong, N., Zalunardo, B., Nishimoto, Y., Sato, Y., Birzulis, J., Skride, A., Zaicenko, A., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Krstevski, G., Bounameaux, H., Mazzolai, L., Bikdeli, B., Caprini, J.A., Bui, H.M., Jaureguízar, Ana, Jiménez, David, Bikdeli, Behnood, Ruiz-Artacho, Pedro, Muriel, Alfonso, Tapson, Victor, López-Reyes, Raquel, Valero, Beatriz, and Kenet, Gili
Published: 2022
Full Text: View/download PDF

7. Thromboprophylaxie pharmacologique chez les patients hospitalisés pour une affection médicale aiguë

Author: Kantor, B., Poénou, G., Plaisance, L., Toledano, E., Mekhloufi, Y., Helfer, H., Djennaoui, S., and Mahé, I.
Published: 2022
Full Text: View/download PDF

8. Timing and characteristics of venous thromboembolism after noncancer surgery

Author: Monreal, Manuel, Prandoni, Paolo, Brenner, Benjamin, Farge-Bancel, Dominique, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Bounameaux, Henri, Malý, Radovan, Verhamme, Peter, Caprini, Joseph A., Bui, Hanh My, Adarraga, M.D., Agud, M., Aibar, J., Aibar, M.A., Amado, C., Arcelus, J.I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Blanco-Molina, A., Botella, E., Camon, A.M., Campos, S., Cañas, I., Casado, I., Castro, J., Criado, J., de Ancos, C., de Miguel, J., Toro, J. del, Demelo-Rodríguez, P., Díaz-Pedroche, C., Díaz-Peromingo, J.A., Díez-Sierra, J., Domínguez, I.M., Escribano, J.C., Falgá, C., Farfán, A.I., Fernández de Roitegui, K., Fernández-Aracil, C., Fernández-Capitán, C., Fernández-Reyes, J.L., Fidalgo, M.A., Flores, K., Font, C., Font, L., Francisco, I., Furest, I., Gabara, C., Galeano-Valle, F., García, M.A., García-Bragado, F., García-Hernáez, R., García-Raso, A., Gavín-Sebastián, O., Gil-Díaz, A., Gómez-Cuervo, C., González-Martínez, J., Grau, E., Giménez-Suau, M., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Hernando, E., Herreros, M., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Jiménez, R., Joya, M.D., Jou, I., Lalueza, A., Lecumberri, R., Lima, J., Llamas, P., Lobo, J.L., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Sáez, J.B., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P.J., Martín del Pozo, M., Martín-Martos, F., Mella, C., Mellado, M., Mercado, M.I., Moisés, J., Monreal, M., Morales, M.V., Muñoz-Blanco, A., Muñoz-Guglielmetti, D., Muñoz-Rivas, N., Nieto, J.A., Núñez-Ares, A., Núñez-Fernández, M.J., Obispo, B., Olivares, M.C., Orcastegui, J.L., Ortega-Recio, M.D., Osorio, J., Otalora, S., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J.M., Pellejero, G., Pesántez, D., Porras, J.A., Portillo, J., Riera-Mestre, A., Rivas, A., Rivera, F., Rodríguez-Cobo, A., Rodríguez-Matute, C., Rogado, J., Rosa, V., Rubio, C.M., Ruiz-Artacho, P., Ruiz-Giménez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J.C., Salgueiro, G., Sampériz, A., Sánchez-Muñoz-Torrero, J.F., Sancho, T., Sigüenza, P., Soler, S., Suriñach, J.M., Torres, M.I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Vela, J.R., Vidal, G., Villares, P., Zamora, C., Gutiérrez, P., Vázquez, F.J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Malý, R., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahé, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Bilora, F., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Di Micco, P., Grandone, E., Marchi, D., Mastroiacovo, D., Maida, R., Pace, F., Pesavento, R., Prandoni, P., Quintavalla, R., Rinzivillo, N., Rocci, A., Siniscalchi, C., Tufano, A., Visonà, A., Zalunardo, B., Gibietis, V., Kigitovica, D., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Krstevski, G., Bounameaux, H., Mazzolai, L., Caprini, J.A., Tafur, A.J., Weinberg, I., Wilkins, H., Bui, H.M., Expósito-Ruiz, Manuela, Arcelus, Juan Ignacio, López-Espada, Cristina, Bura-Riviere, Alessandra, Amado, Cristina, Loring, Mónica, and Mastroiacovo, Daniela
Published: 2021
Full Text: View/download PDF

9. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study

Author: Blondon, Marc, Jimenez, David, Robert‐Ebadi, Helia, Del Toro, Jorge, Lopez‐Jimenez, Luciano, Falga, Conxita, Skride, Andris, Font, Llorenç, Vazquez, Fernando Javier, Bounameaux, Henri, Monreal, Manuel, Prandoni, Paolo, Brenner, Benjamin, Farge‐Bancel, Dominique, Barba, Raquel, Di Micco, Pierpaolo, Bertoletti, Laurent, Schellong, Sebastian, Tzoran, Inna, Reis, Abilio, Bosevski, Marijan, Malý, Radovan, Verhamme, Peter, Caprini, Joseph A, My Bui, Hanh, Adarraga, MD, Agud, M, Aibar, J, Aibar, MA, Alfonso, J, Amado, C, Arcelus, JI, Baeza, C, Ballaz, A, Barba, R, Barbagelata, C, Barrón, M, Barrón‐Andrés, B, Blanco‐Molina, A, Botella, E, Camon, AM, Castro, J, Caudevilla, MA, Cerdà, P, Chasco, L, Criado, J, de Ancos, C, de Miguel, J, Demelo‐Rodríguez, P, Díaz‐Peromingo, JA, Díez‐Sierra, J, Díaz‐Simón, R, Domínguez, IM, Encabo, M, Escribano, JC, Falgá, C, Farfán, AI, Fernández‐Capitán, C, Fernández‐Reyes, JL, Fidalgo, MA, Flores, K, Font, C, Francisco, I, Gabara, C, Galeano‐Valle, F, García, MA, García‐Bragado, F, García‐Mullor, MM, Gavín‐Blanco, O, Gavín‐Sebastián, O, Gil‐Díaz, A, Gómez‐Cuervo, C, González‐Martínez, J, Grau, E, Guirado, L, Gutiérrez, J, Hernández‐Blasco, L, Jara‐Palomares, L, Jaras, MJ, Jiménez, D, Joya, MD, Jou, I, Lacruz, B, Lecumberri, R, Lima, J, Lobo, JL, López‐Brull, H, López‐Jiménez, L, López‐Miguel, P, López‐Núñez, JJ, López‐Reyes, R, López‐Sáez, JB, Lorente, MA, Lorenzo, A, Loring, M, Madridano, O, Maestre, A, Marchena, PJ, Martín del Pozo, M, Martín‐Martos, F, Martínez‐Baquerizo, C, Mella, C, Mellado, M, Mercado, MI, Moisés, J, Morales, MV, Muñoz‐Blanco, A, Muñoz‐Guglielmetti, D, Muñoz‐Rivas, N, Nart, E, Nieto, JA, Núñez, MJ, Olivares, MC, Ortega‐Michel, C, Ortega‐Recio, MD, Osorio, J, Otalora, S, Otero, R, Parra, P, Parra, V, Pedrajas, JM, Pellejero, G, Pérez‐Jacoiste, A, Peris, ML, Pesántez, D, Porras, JA, Portillo, J, Reig, L, Riera‐Mestre, A, Rivas, A, Rodríguez‐Cobo, A, Rodríguez‐Matute, C, Rogado, J, Rosa, V, Rubio, CM, Ruiz‐Artacho, P, Ruiz‐Giménez, N, Ruiz‐Ruiz, J, Ruiz‐Sada, P, Sahuquillo, JC, Salgueiro, G, Sampériz, A, Sánchez‐Muñoz‐Torrero, JF, Sancho, T, Sigüenza, P, Sirisi, M, Soler, S, Suárez, S, Suriñach, JM, Tiberio, G, Torres, MI, Tolosa, C, Trujillo‐Santos, J, Uresandi, F, Usandizaga, E, Valle, R, Vela, JR, Vidal, G, Vilar, C, Villares, P, Zamora, C, Gutiérrez, P, Vázquez, FJ, Vanassche, T, Vandenbriele, C, Verhamme, P, Hirmerova, J, Malý, R, Salgado, E, Benzidia, I, Bertoletti, L, Bura‐Riviere, A, Crichi, B, Debourdeau, P, Espitia, O, Farge‐Bancel, D, Helfer, H, Mahé, I, Moustafa, F, Poenou, G, Schellong, S, Braester, A, Brenner, B, Tzoran, I, Amitrano, M, Bilora, F, Bortoluzzi, C, Brandolin, B, Ciammaichella, M, Colaizzo, D, Dentali, F, Di Micco, P, Giammarino, E, Grandone, E, Mangiacapra, S, Mastroiacovo, D, Maida, R, Mumoli, N, Pace, F, Pesavento, R, Pomero, F, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tufano, A, Visonà, A, Vo Hong, N, Zalunardo, B, Kalejs, RV, Maķe, K, Ferreira, M, Fonseca, S, Martins, F, Meireles, J, Bosevski, M, Zdraveska, M, Mazzolai, L, Caprini, JA, Tafur, AJ, Weinberg, I, Wilkins, H, and Bui, HM
Published: 2021
Full Text: View/download PDF

10. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

Author: Adarraga, M.D., Agud, M., Aibar, J., Aibar, M.A., Amado, C., Arcelus, J.I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barrón, M., Barrón-Andrés, B., Bernal, M., Blanco-Molina, A., Botella, E., Camon, A.M., Cañas, I., Casado, I., Castro, J., Chasco, L., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodríguez, P., Díaz-Peromingo, J.A., Di Campli, M.V., Díez-Sierra, J., Domínguez, I.M., Encabo, M., Escribano, J.C., Falgá, C., Farfán-Sedano, A.I., Fernández de Roitegui, K., Fernández-Capitán, C., Fernández-Reyes, J.L., Fidalgo, M.A., Flores, K., Font, C., Font, L., Francisco, I., Furest, I., Gabara, C., Galeano-Valle, F., García, M.A., García-Bragado, F., García de Herreros, M., García-Hernáez, R., García-Mullor, M.M., García-Raso, A., Gavín-Sebastián, O., Gil-Díaz, A., Gómez-Cuervo, C., González-Martínez, J., Grau, E., Giménez-Suau, M., Guirado, L., Gutiérrez, J., Hernández-Blasco, L., Hernando, E., Jara-Palomares, L., Jaras, M.J., Jiménez, D., Joya, M.D., Jou, I., Lima, J., Llamas, P., Lobo, J.L., López-Jiménez, L., López-Miguel, P., López-Núñez, J.J., López-Reyes, R., López-Sáez, J.B., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P.J., Martín del Pozo, M., Martín-Martos, F., Mella, C., Mellado, M., Mercado, M.I., Moisés, J., Monreal, M., Morales, M.V., Muñoz-Blanco, A., Muñoz-Guglielmetti, D., Muñoz-Rivas, N., Navas, M.S., Nieto, J.A., Núñez-Ares, A., Núñez-Fernández, M.J., Obispo, B., Olid, M., Olivares, M.C., Orcastegui, J.L., Ortega-Recio, M.D., Osorio, J., Otalora, S., Otero, R., Parra, P., Parra, V., Pedrajas, J.M., Peinado, A., Pellejero, G., Pérez-Jacoiste, A., Porras, J.A., Portillo, J., Riera-Mestre, A., Rivas, A., Rivera, F., Rodríguez-Chiaradía, D.A., Rodríguez-Cobo, A., Rodríguez-Matute, C., Rogado, J., Rojo, R., Rosa, V., Ruiz-Artacho, P., Ruiz-Giménez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J.C., Salgueiro, G., Sampériz, A., Sánchez-Martínez, R., Sánchez-Muñoz-Torrero, J.F., Sancho, T., Soler, S., Suriñach, J.M., Tirado, R., Torres, M.I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Vela, J.R., Vidal, G., Villares, P., Zamora, C., Gutiérrez, P., Vázquez, F.J., Engelen, M., Vanassche, T., Vehamme, P., Hirmerova, J., Malý, R., Ait Abdallah, N., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahé, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Bilora, F., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Di Micco, P., Grandone, E., Imbalzano, E., Maida, R., Mastroiacovo, D., Pace, F., Pesavento, R., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visonà, A., Zalunardo, B., Skride, A., Strautmane, S., Zaicenko, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Bounameaux, H., Mazzolai, L., Caprini, J.A., Tafur, A.J., Weinberg, I., Wilkins, H., Bui, H.M., Núñez Fernández, Manuel J., Martínez Reglero, Cristina, Nieto Rodríguez, José Antonio, Chouza Piñeiro, Ana, Barcia Sixto, Laura, Maestre Peiró, Ana, Trujillo Santos, Javier, Visonà, Adriana, Fernández-Reyes, José Luis, and Monreal Bosch, Manuel
Published: 2020
Full Text: View/download PDF

11. Educational diagnosis of patients under oral anticoagulant therapy: Development of a 4-category patient profiling score based on a retrospective study and prospective analysis

Author: Ostrowka, C., Journeau, L., Plaisance, L., Poenou, G., Mecherour, S.E., Helfer, H., and Mahé, I.
Published: 2020
Full Text: View/download PDF

12. PB0951 Are Efficacy and Safety of Direct Oral Anticoagulants Modified by Fragility Characteristics in Patients with Cancer Associated Thrombosis (CAT)? A Meta-Analysis of Randomized Controlled Trials

Author: Laporte, S., primary, Chapelle, C., additional, Marshall, A., additional, Mismetti, V., additional, Poenou, G., additional, Hanon, O., additional, Sanchez, O., additional, Mahe, I., additional, and Young, A., additional
Published: 2023
Full Text: View/download PDF

13. PB0956 Performance of Score in CAT Prediction in the Setting of Different Subtypes of Digestive Cancer from ONCOCIP Database

Author: Poenou, G., primary, Dumitru Dumitru, T., additional, Presles, E., additional, Mismetti, V., additional, Chauvin, F., additional, Laporte, S., additional, and Bertoletti, L., additional
Published: 2023
Full Text: View/download PDF

14. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

Author: Cohen, Omri, primary, Barg, Assaf A., additional, Nowak-Göttl, Ulrike, additional, Amado-Fernández, Cristina, additional, Mazzolai, Lucia, additional, Tiberio, Gregorio, additional, Schellong, Sebastian, additional, Skride, Andris, additional, Morales, María del Valle, additional, Monreal, Manuel, additional, Kenet, Gili, additional, Prandoni, Paolo, additional, Brenner, Benjamin, additional, Farge-Bancel, Dominique, additional, Barba, Raquel, additional, Di Micco, Pierpaolo, additional, Bertoletti, Laurent, additional, Tzoran, Inna, additional, Reis, Abilio, additional, Bosevski, Marijan, additional, Bounameaux, Henri, additional, Malý, Radovan, additional, Verhamme, Peter, additional, Caprini, Joseph A., additional, Bui, Hanh My, additional, Adarraga, M.D., additional, Alberich-Conesa, A., additional, Alonso-Carrillo, J., additional, Amado, C., additional, Amorós, S., additional, Arcelus, J.I., additional, Ballaz, A., additional, Barba, R., additional, Barbagelata, C., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Blanco-Molina, A., additional, Botella, E., additional, Casado, I., additional, Chasco, L., additional, Cerdà, P., additional, Criado, J., additional, del Toro, J., additional, De Juana-Izquierdo, C., additional, Demelo-Rodríguez, P., additional, Díaz-Brasero, A.M., additional, Díaz-Pedroche, M.C., additional, Díaz-Peromingo, J.A., additional, Dubois-Silva, A., additional, Escribano, J.C., additional, Espósito, F., additional, Falgá, C., additional, Fernández-Capitán, C., additional, Fernández-Jiménez, B., additional, Fernández-Muixi, J., additional, Fernández-Reyes, J.L., additional, Fidalgo, M.A., additional, Font, C., additional, Francisco, I., additional, Galeano-Valle, F., additional, García, M.A., additional, García de Herreros, M., additional, García-Bragado, F., additional, García-Ortega, A., additional, Gavín-Sebastián, O., additional, Gil-Díaz, A., additional, Gómez-Cuervo, C., additional, Gómez-Mosquera, A.M., additional, González-Martínez, J., additional, González-Moreno, M., additional, Grau, E., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández-Blasco, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Jou, I., additional, Joya, M.D., additional, Lacruz, B., additional, Lainez-Justo, S., additional, Lalueza, A., additional, Latorre, A., additional, Lecumberri, R., additional, Lobo, J.L., additional, López-De la Fuente, M., additional, López-Jiménez, L., additional, López-Miguel, P., additional, López-Núñez, J.J., additional, López-Ruiz, A., additional, López-Sáez, J.B., additional, Lorenzo, A., additional, Lumbierres, M., additional, Madridano, O., additional, Maestre, A., additional, Marcos, M., additional, Martín-Martos, F., additional, Mellado, M., additional, Mena, E., additional, Mercado, M.I., additional, Moisés, J., additional, Monreal, M., additional, Muñoz-Blanco, A., additional, Muñoz-Gamito, G., additional, Morales, M.V., additional, Nieto, J.A., additional, Noguera-Gras, E., additional, Núñez-Fernández, M.J., additional, Osorio, J., additional, Otalora, S., additional, Pacheco-Gómez, N., additional, Paredes-Ruiz, D., additional, Parra, P., additional, Pedrajas, J.M., additional, Pérez-Ductor, C., additional, Pérez-Jacoiste, M.A., additional, Pérez-Pérez, J.L., additional, Peris, M.L., additional, Porras, J.A., additional, Poyo-Molina, J., additional, Puchades, R., additional, Riera-Mestre, A., additional, Rivera-Civico, F., additional, Rivera-Gallego, A., additional, Roca, M., additional, Rosa, V., additional, Rodríguez-Cobo, A., additional, Ruiz-Giménez, N., additional, Salgueiro, G., additional, Sancho, T., additional, Sendín, V., additional, Sigüenza, P., additional, Soler, S., additional, Suriñach, J.M., additional, Tiberio, G., additional, Torres, M.I., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Usandizaga, E., additional, Valle, R., additional, Varona, J.F., additional, Vela, L., additional, Vela, J.R., additional, Villalobos, A., additional, Villares, P., additional, Ay, C., additional, Nopp, S., additional, Pabinger, I., additional, Engelen, M.M., additional, Martens, C., additional, Verhamme, P., additional, Yoo, H.H.B., additional, Arguello, J.D., additional, Montenegro, A.C., additional, Roa, J., additional, Hirmerova, J., additional, Malý, R., additional, Accassat, S., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Catella, J., additional, Chopard, R., additional, Couturaud, F., additional, Espitia, O., additional, Leclercq, B., additional, Le Mao, R., additional, Mahé, I., additional, Moustafa, F., additional, Plaisance, L., additional, Poenou, G., additional, Sarlon-Bartoli, G., additional, Suchon, P., additional, Versini, E., additional, Schellong, S., additional, Braester, A., additional, Brenner, B., additional, Kenet, G., additional, Tzoran, I., additional, Sadeghipour, P., additional, Basaglia, M., additional, Bilora, F., additional, Bortoluzzi, C., additional, Brandolin, B., additional, Ciammaichella, M., additional, Colaizzo, D., additional, De Angelis, A., additional, Dentali, F., additional, Di Micco, P., additional, Grandone, E., additional, Imbalzano, E., additional, Merla, S., additional, Pesavento, R., additional, Prandoni, P., additional, Scarinzi, P., additional, Siniscalchi, C., additional, Tufano, A., additional, Visonà, A., additional, Vo Hong, N., additional, Zalunardo, B., additional, Gibietis, V., additional, Kigitovica, D., additional, Skride, A., additional, Fonseca, S., additional, Manuel, M., additional, Meireles, J., additional, Bosevski, M., additional, Bounameaux, H., additional, Mazzolai, L., additional, Aujayeb, A., additional, Caprini, J.A., additional, Weinberg, I., additional, and Bui, H.M., additional
Published: 2023
Full Text: View/download PDF

15. Towards optimal use of antithrombotic therapy of people with cancer at the end of life:A research protocol for the development and implementation of the SERENITY shared decision support tool

Author: Goedegebuur, J., Abbel, D., Accassat, S., Achterberg, W. P., Akbari, A., Arfuch, V. M., Baddeley, E., Bax, J. J., Becker, D., Bergmeijer, B., Bertoletti, L., Blom, J. W., Calvetti, A., Cannegieter, S. C., Castro, L., Chavannes, N. H., Coma-Auli, N., Couffignal, C., Edwards, A., Edwards, M., Enggaard, H., Font, C., Gava, A., Geersing, G. J., Geijteman, E. C.T., Greenley, S., Gregory, C., Gussekloo, J., Hoffmann, I., Højen, A. A., van den Hout, W. B., Huisman, M. V., Jacobsen, S., Jagosh, J., Johnson, M. J., Jørgensen, L., Juffermans, C. C.M., Kempers, E. K., Konstantinides, S., Kroder, A. F., Kruip, M. J.H.A., Lafaie, L., Langendoen, J. W., Larsen, T. B., Lifford, K., van der Linden, Y. M., Mahé, I., Maiorana, L., Maraveyas, A., Martens, E. S.L., Mayeur, D., van Mens, T. E., Mohr, K., Mooijaart, S. P., Murtagh, F. E.M., Nelson, A., Nielsen, P. B., Ording, A. G., Ørskov, M., Pearson, M., Poenou, G., Portielje, J. E.A., Raczkiewicz, D., Rasmussen, K., Trinks-Roerdink, E., Schippers, I., Seddon, K., Sexton, K., Sivell, S., Skjøth, F., Søgaard, M., Szmit, S., Trompet, S., Vassal, P., Visser, C., van Vliet, L. M., Wilson, E., Klok, F. A., Noble, S. I.R., Goedegebuur, J., Abbel, D., Accassat, S., Achterberg, W. P., Akbari, A., Arfuch, V. M., Baddeley, E., Bax, J. J., Becker, D., Bergmeijer, B., Bertoletti, L., Blom, J. W., Calvetti, A., Cannegieter, S. C., Castro, L., Chavannes, N. H., Coma-Auli, N., Couffignal, C., Edwards, A., Edwards, M., Enggaard, H., Font, C., Gava, A., Geersing, G. J., Geijteman, E. C.T., Greenley, S., Gregory, C., Gussekloo, J., Hoffmann, I., Højen, A. A., van den Hout, W. B., Huisman, M. V., Jacobsen, S., Jagosh, J., Johnson, M. J., Jørgensen, L., Juffermans, C. C.M., Kempers, E. K., Konstantinides, S., Kroder, A. F., Kruip, M. J.H.A., Lafaie, L., Langendoen, J. W., Larsen, T. B., Lifford, K., van der Linden, Y. M., Mahé, I., Maiorana, L., Maraveyas, A., Martens, E. S.L., Mayeur, D., van Mens, T. E., Mohr, K., Mooijaart, S. P., Murtagh, F. E.M., Nelson, A., Nielsen, P. B., Ording, A. G., Ørskov, M., Pearson, M., Poenou, G., Portielje, J. E.A., Raczkiewicz, D., Rasmussen, K., Trinks-Roerdink, E., Schippers, I., Seddon, K., Sexton, K., Sivell, S., Skjøth, F., Søgaard, M., Szmit, S., Trompet, S., Vassal, P., Visser, C., van Vliet, L. M., Wilson, E., Klok, F. A., and Noble, S. I.R.
Abstract: Background: Even though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs. Methods: The SERENITY consortium comprises researchers and clinicians from eight European countries with specialties in different clinical fields, epidemiology and psychology. SERENITY will use a comprehensive approach combining a realist review, flash mob research, epidemiological studies, and qualitative interviews. The results of these studies will be used in a Delphi process to reach a consensus on the optimal design of the shared decision support tool. Next, the shared decision support tool will be tested in a randomised controlled trial. A targeted implementation and dissemination plan will be developed to enable the use of the SERENITY tool across Europe, as well as its incorporation in clinical guidelines and policies. The entire project is funded by Horizon Europe. Results: SERENITY will develop an information-driven shared decision support tool that will facilitate treatment decisions regarding the appropriate use of antithrombotic therapy in people with cancer at the end of life. Conclusions: We aim to develop an intervention that guides the appropriate use of antithrombotic therapy, prevents bleeding complications, and saves healthcare costs. Hopefully, usage of the tool leads to enhanced empowerment and improved quality of life and treatment satisfaction of people with advanced cancer and their care givers.
Published: 2023

16. Maladie thromboembolique veineuse associée au cancer : combien de patients atteints de cancer du poumon vus en pratique clinique seraient éligibles à un essai contrôlé randomisé sur les AODs ?

Author: Petit, B., primary, Mismetti, V., additional, Soudet, S., additional, Poenou, G., additional, Zarrat, E., additional, Machuron, T., additional, Accassat, S., additional, Plaisance, L., additional, Helfer, H., additional, Le Hello, C., additional, Sevestre, M.A., additional, Mahé, I., additional, and Bertoletti, L., additional
Published: 2023
Full Text: View/download PDF

17. Cancer Associated Thrombosis:how many lung cancer patients seen in clinical practice would be eligible to a DOAC randomized controlled trial?

Author: Petit, B, primary, Mismetti, V, additional, Soudet, S, additional, Poenou, G, additional, Zarrat, E, additional, Machuron, T, additional, Acassat, S, additional, Plaisance, L, additional, Helfer, H, additional, Le Hello, C, additional, Sevestre, M, additional, Mahé, I, additional, and Bertoletti, L, additional
Published: 2022
Full Text: View/download PDF

18. Myocardite immuno-médiée : toxicité rare, grave et létale des inhibiteurs de points de contrôle immunitaire

Author: Kaakoua, M., primary, Djenaoui, S., additional, Joseph, N., additional, Mohamed, A., additional, Zanardo, L., additional, Samy, E., additional, Poenou, G., additional, Chidiac, J., additional, and Mahe, I., additional
Published: 2022
Full Text: View/download PDF

19. PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

Author: Petit, B., primary, Soudet, S., additional, Poenou, G., additional, Zarrat, E., additional, Machuron, T., additional, Accassat, S., additional, Plaisance, L., additional, Helfer, H., additional, Mismetti, V., additional, Le Hello, C., additional, Sevestre, M.-A., additional, Mahé, I., additional, and Bertoletti, L., additional
Published: 2022
Full Text: View/download PDF

20. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

Author: Camporese, G., Simioni, P., Di Micco, P., Fernandez-Capitan, C., Rivas, A., Font, C., Sahuquillo, J. C., Villares, P., Prandoni, P., Monreal, M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Arcelus, J. I., Baeza, C., Ballaz, A., Barba, R., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Castro, J., Caudevilla, M. A., Cerda, P., Chasco, L., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodriguez, P., Diaz-Peromingo, J. A., Diez-Sierra, J., Dominguez, I. M., Encabo, M., Escribano, J. C., Falga, C., Farfan, A. I., Fernandez de Roitegui, K., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Mullor, M. M., Gavin-Blanco, O., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Joya, M. D., Jou, I., Lacruz, B., Lalueza, A., Lecumberri, R., Lima, J., Lobo, J. L., Lopez-Brull, H., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Baquerizo, C., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Munoz-Rivas, N., Nart, E., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Recio, M. D., Osorio, J., Otalora, S., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Peris, M. L., Pesantez, D., Porras, J. A., Portillo, J., Ramos, E., Reig, L., Riera-Mestre, A., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rogado, J., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Siguenza, P., Sirisi, M., Soler, S., Suarez, S. Surinach J. M., Tiberio, G., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vidal, G., Vilar, C., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., Dentali, F., Giammarino, E., Grandone, E., Mangiacapra, S., Mastroiacovo, D., Maida, R., Mumoli, N., Pace, F., Pesavento, R., Pomero, F., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Make, K., Meilanden, K., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J. A., Tafur, A. J., Weinberg, I., Wilkins, H., Bui, H. M., and UAM. Departamento de Medicina
Subjects: Male, medicine.medical_specialty, Time Factors, Dose, Medicina, Pyridines, Hemorrhage, General Biochemistry, Genetics and Molecular Biology, Article, chemistry.chemical_compound, Edoxaban, Recurrence, Internal medicine, medicine, Humans, Prospective Studies, Registries, General Pharmacology, Toxicology and Pharmaceutics, Long term therapy, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Tapering, business.industry, lcsh:Public aspects of medicine, General Neuroscience, Mortality rate, Research, lcsh:RM1-950, Hazard ratio, Anticoagulants, lcsh:RA1-1270, General Medicine, Articles, Venous Thromboembolism, Middle Aged, Confidence interval, Thiazoles, lcsh:Therapeutics. Pharmacology, chemistry, Practice Guidelines as Topic, Dose reduction, Female, business, Venous thromboembolism, Follow-Up Studies
Abstract: Edoxaban is used for venous thromboembolism (VTE) treatment. Real-life data are lacking about its use in long-term therapy. We aimed to assess the efficacy and the safety of edoxaban for long-term VTE treatment in a real-life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis to identify predictors for the composite outcome was performed. From October 2015 to November 2019, 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, two patients developed recurrent VTE, six had major bleeding and nine died (2 from fatal bleeding). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio (HR) 8.37; 95% confidence interval (CI) 1.12–42.4) and a significant higher mortality rate (HR 31.1; 95% CI 4.63–262) than those receiving 60 mg. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no events, and a nonsignificantly higher mortality rate (HR 5.04; 95% CI 0.54–133) than those receiving 30 mg daily. In conclusion, edoxaban seems to be effective and safe for long-term VTE treatment in real life. Criteria for dose reduction should be reformulated., No funding was received for this work
Published: 2020

21. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

Author: Jaureguízar, Ana, primary, Jiménez, David, additional, Bikdeli, Behnood, additional, Ruiz-Artacho, Pedro, additional, Muriel, Alfonso, additional, Tapson, Victor, additional, López-Reyes, Raquel, additional, Valero, Beatriz, additional, Kenet, Gili, additional, Monreal, Manuel, additional, Prandoni, Paolo, additional, Brenner, Benjamin, additional, Farge-Bancel, Dominique, additional, Barba, Raquel, additional, Di Micco, Pierpaolo, additional, Bertoletti, Laurent, additional, Schellong, Sebastian, additional, Tzoran, Inna, additional, Reis, Abilio, additional, Bosevski, Marijan, additional, Bounameaux, Henri, additional, Malý, Radovan, additional, Verhamme, Peter, additional, Caprini, Joseph A., additional, Bui, Hanh My, additional, Adarraga, M.D., additional, Aibar, J., additional, Aibar, M.A., additional, Alonso, J., additional, Amado, C., additional, Arcelus, J.I., additional, Asuero, A., additional, Azcarate-Agüero, P., additional, Ballaz, A., additional, Barba, R., additional, Barbagelata, C., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Blanco-Molina, A., additional, Beddar Chaib, F., additional, Camon, A.M., additional, Castro, J., additional, Chasco, L., additional, Criado, J., additional, de Ancos, C., additional, del Toro, J., additional, Demelo-Rodríguez, P., additional, Díaz-Brasero, A.M., additional, Díaz-Pedroche, M.C., additional, Díaz-Peromingo, J.A., additional, Di Campli, M.V., additional, Dubois-Silva, A., additional, Escribano, J.C., additional, Espósito, F., additional, Farfán-Sedano, A.I., additional, Fernández-Capitán, C., additional, Fernández-Reyes, J.L., additional, Fidalgo, M.A., additional, Flores, K., additional, Font, C., additional, Font, L., additional, Francisco, I., additional, Gabara, C., additional, Galeano-Valle, F., additional, García, M.A., additional, García-Bragado, F., additional, García de Herreros, M., additional, García de la Garza, R., additional, García-Díaz, C., additional, Gil-Díaz, A., additional, Gómez-Cuervo, C., additional, Giménez-Suau, M., additional, Grau, E., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández-Blasco, L., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Jiménez-Alfaro, C., additional, Joya, M.D., additional, Lainez-Justo, S., additional, Latorre, A., additional, Lima, J., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Miguel, P., additional, López-Núñez, J.J., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorenzo, A., additional, Madridano, O., additional, Maestre, A., additional, Marchena, P.J., additional, Martín del Pozo, M., additional, Martín-Martos, F., additional, Martínez-Urbistondo, D., additional, Mella, C., additional, Mercado, M.I., additional, Moisés, J., additional, Monreal, M., additional, Muñoz, M., additional, Muñoz-Blanco, A., additional, Nieto, J.A., additional, Nofuentes-Pérez, E., additional, Núñez-Fernández, M.J., additional, Olid-Velilla, M., additional, Olivares, M.C., additional, Osorio, J., additional, Otalora, S., additional, Otero, R., additional, Pedrajas, J.M., additional, Pellejero, G., additional, Porras, J.A., additional, Portillo, J., additional, Rodríguez-Matute, C., additional, Rosa, V., additional, Ruiz-Artacho, P., additional, Ruiz-Ruiz, J., additional, Salgueiro, G., additional, Sánchez-Martínez, R., additional, Sánchez-Muñoz-Torrero, J.F., additional, Sancho, T., additional, Soler, S., additional, Suárez-Rodríguez, B., additional, Suriñach, J.M., additional, Torres, M.I., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valero, B., additional, Valle, R., additional, Varona, J.F., additional, Vela, L., additional, Vela, J.R., additional, Vidal, G., additional, Villalobos, A., additional, Villares, P., additional, Zamora, C., additional, Ay, C., additional, Nopp, S., additional, Pabinger, I., additional, Vanassche, T., additional, Vandenbriele, C., additional, Verhamme, P., additional, Hirmerova, J., additional, Malý, R., additional, Accassat, S., additional, Ait Abdallah, N., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Catella, J., additional, Couturaud, F., additional, Crichi, B., additional, Debourdeau, P., additional, Espitia, O., additional, Farge-Bancel, D., additional, Grange, C., additional, Helfer, H., additional, Lacut, K., additional, Le Mao, R., additional, Mahé, I., additional, Morange, P., additional, Moustafa, F., additional, Poenou, G., additional, Sarlon-Bartoli, G., additional, Suchon, P., additional, Quere, I., additional, Schellong, S., additional, Braester, A., additional, Brenner, B., additional, Kenet, G., additional, Tzoran, I., additional, Basaglia, M., additional, Bilora, F., additional, Bortoluzzi, C., additional, Brandolin, B., additional, Ciammaichella, M., additional, De Angelis, A., additional, Di Micco, P., additional, Imbalzano, E., additional, Merla, S., additional, Pesavento, R., additional, Prandoni, P., additional, Siniscalchi, C., additional, Tufano, A., additional, Visonà, A., additional, Vo Hong, N., additional, Zalunardo, B., additional, Nishimoto, Y., additional, Sato, Y., additional, Birzulis, J., additional, Skride, A., additional, Zaicenko, A., additional, Fonseca, S., additional, Martins, F., additional, Meireles, J., additional, Bosevski, M., additional, Krstevski, G., additional, Bounameaux, H., additional, Mazzolai, L., additional, Bikdeli, B., additional, Caprini, J.A., additional, and Bui, H.M., additional
Published: 2022
Full Text: View/download PDF

22. Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

Author: Petit, B., Soudet, S., Poenou, G., Zarrat, E., Machuron, T., Accassat, S., Plaisance, L., Helfer, H., Mismetti, V., Le Hello, C., Pietri-Sevestre, Marie-Antoinette, Mahe, I., Bertoletti, L., and DESSAIVRE, Louise
Subjects: [SDV] Life Sciences [q-bio]
Published: 2022

23. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

Author: Martinez-Urbistondo D., de la Garza R. G., Villares-Fernandez P., Font C., Schellong S., Lopez-Nunez J. J., Gil-Diaz A., del Carmen Diaz-Pedroche M., Hirmerova J., Monreal M., Adarraga M., Aibar J., Alonso J., Amado C., Arcelus J., Asuero A., Ballaz A., Barba R., Barbagelata C., Barron M., Barron-Andres B., Blanco-Molina A., Beddar Chaib F., Botella E., Castro J., Chasco L., Criado J., de Ancos C., del Toro J., Demelo-Rodriguez P., Diaz-Brasero A., Diaz-Pedroche M., Diaz-Peromingo J., Di Campli M., Dubois-Silva A., Escribano J., Esposito F., Farfan-Sedano A., Fernandez-Capitan C., Fernandez-Reyes J., Fidalgo M., Flores K., Font L., Francisco I., Gabara C., Galeano-Valle F., Garcia M., Garcia-Bragado F., Garcia de Herreros M., de la Garza R., Garcia-Diaz C., Gomez-Cuervo C., Grau E., Guirado L., Gutierrez J., Hernandez-Blasco L., Jara-Palomares L., Jaras M., Jimenez D., Jimenez R., Jimenez-Alfaro C., Joya M., Lainez-Justo S., Lalueza A., Latorre A., Lima J., Lobo J., Lopez-Jimenez L., Lopez-Miguel P., Lopez-Nunez J., Lopez-Reyes R., Lopez-Saez J., Lorenzo A., Madridano O., Maestre A., Marchena P., Martin del Pozo M., Martin-Martos F., Mella C., Mercado M., Moises J., Munoz-Blanco A., Nieto J., Nofuentes-Perez E., Nunez-Fernandez M., Olid-Velilla M., Olivares M., Osorio J., Otalora S., Otero R., Paredes D., Pedrajas J., Porras J., Portillo J., Redondo I., Rodriguez-Matute C., Rosa V., Ruiz-Artacho P., Ruiz-Ruiz J., Salgueiro G., Sanchez-Martinez R., Sanchez-Munoz-Torrero J., Sancho T., Soler S., Suarez-Rodriguez B., Surinach J., Torres M., Torres-Sanchez A., Tolosa C., Trujillo-Santos J., Uresandi F., Valero B., Valle R., Varona J., Vela L., Vela J., Vidal G., Villalobos A., Villares P., Zamora C., Ay C., Nopp S., Pabinger I., Engelen M., Vanassche T., Verhamme P., Maly R., Accassat S., Ait Abdallah N., Bertoletti L., Bura-Riviere A., Catella J., Couturaud F., Crichi B., Debourdeau P., Espitia O., Farge-Bancel D., Grange C., Helfer H., Lacut K., Le Mao R., Mahe I., Morange P., Moustafa F., Poenou G., Sarlon-Bartoli G., Suchon P., Quere I., Braester A., Brenner B., Kenet G., Tzoran I., Basaglia M., Bilora F., Bortoluzzi C., Brandolin B., Ciammaichella M., De Angelis A., Di Micco P., Imbalzano E., Merla S., Pesavento R., Prandoni P., Siniscalchi C., Tufano A., Visona A., Vo Hong N., Zalunardo B., Nishimoto Y., Sato Y., Make K., Skride A., Strautmane S., Fonseca S., Martins F., Meireles J., Bosevski M., Bounameaux H., Mazzolai L., Caprini J., Bui H., Martinez-Urbistondo, D., de la Garza, R. G., Villares-Fernandez, P., Font, C., Schellong, S., Lopez-Nunez, J. J., Gil-Diaz, A., del Carmen Diaz-Pedroche, M., Hirmerova, J., Monreal, M., Adarraga, M., Aibar, J., Alonso, J., Amado, C., Arcelus, J., Asuero, A., Ballaz, A., Barba, R., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Beddar Chaib, F., Botella, E., Castro, J., Chasco, L., Criado, J., de Ancos, C., del Toro, J., Demelo-Rodriguez, P., Diaz-Brasero, A., Diaz-Pedroche, M., Diaz-Peromingo, J., Di Campli, M., Dubois-Silva, A., Escribano, J., Esposito, F., Farfan-Sedano, A., Fernandez-Capitan, C., Fernandez-Reyes, J., Fidalgo, M., Flores, K., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M., Garcia-Bragado, F., Garcia de Herreros, M., de la Garza, R., Garcia-Diaz, C., Gomez-Cuervo, C., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M., Jimenez, D., Jimenez, R., Jimenez-Alfaro, C., Joya, M., Lainez-Justo, S., Lalueza, A., Latorre, A., Lima, J., Lobo, J., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J., Lopez-Reyes, R., Lopez-Saez, J., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P., Martin del Pozo, M., Martin-Martos, F., Mella, C., Mercado, M., Moises, J., Munoz-Blanco, A., Nieto, J., Nofuentes-Perez, E., Nunez-Fernandez, M., Olid-Velilla, M., Olivares, M., Osorio, J., Otalora, S., Otero, R., Paredes, D., Pedrajas, J., Porras, J., Portillo, J., Redondo, I., Rodriguez-Matute, C., Rosa, V., Ruiz-Artacho, P., Ruiz-Ruiz, J., Salgueiro, G., Sanchez-Martinez, R., Sanchez-Munoz-Torrero, J., Sancho, T., Soler, S., Suarez-Rodriguez, B., Surinach, J., Torres, M., Torres-Sanchez, A., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valero, B., Valle, R., Varona, J., Vela, L., Vela, J., Vidal, G., Villalobos, A., Villares, P., Zamora, C., Ay, C., Nopp, S., Pabinger, I., Engelen, M., Vanassche, T., Verhamme, P., Maly, R., Accassat, S., Ait Abdallah, N., Bertoletti, L., Bura-Riviere, A., Catella, J., Couturaud, F., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Grange, C., Helfer, H., Lacut, K., Le Mao, R., Mahe, I., Morange, P., Moustafa, F., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Quere, I., Braester, A., Brenner, B., Kenet, G., Tzoran, I., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., De Angelis, A., Di Micco, P., Imbalzano, E., Merla, S., Pesavento, R., Prandoni, P., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Nishimoto, Y., Sato, Y., Make, K., Skride, A., Strautmane, S., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Bounameaux, H., Mazzolai, L., Caprini, J., and Bui, H.
Subjects: medicine.medical_specialty, VTE risk assessment, Healthy individual, Elevated liver enzymes, Hemorrhage, Gastroenterology, Liver disease, Recurrence, Fibrosis, Internal medicine, Internal Medicine, medicine, Anticoagulation adverse event, Humans, In patient, Registries, Clinical VTE, business.industry, Liver Diseases, Anticoagulants, Venous Thromboembolism, medicine.disease, Im - Original, Non-invasive liver assessment, Healthy individuals, Increased risk, Anticoagulant therapy, Emergency Medicine, Anticoagulation adverse events, business, Venous thromboembolism, Major bleeding
Abstract: The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10–2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04–2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation. Supplementary Information The online version contains supplementary material available at 10.1007/s11739-021-02858-x.
Published: 2021

24. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project

Author: Tafur, A., Bikdeli, B., Weinberg, I., Jimenez, D., Monreal, A., Barba, R., Mira, E., Macrinici, V., Krumholz, H. M., Hawkins, M., Monreal, M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Arcelus, J. I., Baeza, C., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Canas, I., Castro, J., Cerda, P., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodriguez, P., Diaz-Peromingo, J. A., Diez-Sierra, J., Diaz-Simon, R., Dominguez, I. M., Encabo, M., Escribano, J. C., Falga, C., Farfan, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Mullor, M. M., Gavin-Blanco, O., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Joya, M. D., Jou, I., Lacruz, B., Lecumberri, R., Lima, J., Lobo, J. L., Lopez-Brull, H., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Guerra, J. M., Martin-Martos, F., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Michel, C., Ortega-Recio, M. D., Osorio, J., Otero, R., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Perez-Jacoiste, A., Peris, M. L., Pesantez, D., Porras, J. A., Ramos, E., Reig, L., Riera-Mestre, A., Rivas, A., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J. C., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Soler, S., Suarez, S., Surinach, J. M., Tiberio, G., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vidal, G., Villares, P., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Dentali, F., Di Micco, P., Giammarino, E., Grandone, E., Mangiacapra, S., Mastroiacovo, D., Maida, R., Mumoli, N., Pace, F., Pesavento, R., Pomero, F., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Gibietis, V., Kigitovica, D., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J. A., Tafur, A. J., Wilkins, H., Bui, H. M., Tafur, A., Bikdeli, B., Weinberg, I., Jimenez, D., Monreal, A., Barba, R., Mira, E., Macrinici, V., Krumholz, H. M., Hawkins, M., Monreal, M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Arcelus, J. I., Baeza, C., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Canas, I., Castro, J., Cerda, P., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodriguez, P., Diaz-Peromingo, J. A., Diez-Sierra, J., Diaz-Simon, R., Dominguez, I. M., Encabo, M., Escribano, J. C., Falga, C., Farfan, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Mullor, M. M., Gavin-Blanco, O., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Joya, M. D., Jou, I., Lacruz, B., Lecumberri, R., Lima, J., Lobo, J. L., Lopez-Brull, H., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Guerra, J. M., Martin-Martos, F., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Michel, C., Ortega-Recio, M. D., Osorio, J., Otero, R., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Perez-Jacoiste, A., Peris, M. L., Pesantez, D., Porras, J. A., Ramos, E., Reig, L., Riera-Mestre, A., Rivas, A., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J. C., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Soler, S., Suarez, S., Surinach, J. M., Tiberio, G., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vidal, G., Villares, P., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Verhamme, P., Hirmerova, J., Maly, R., Salgado, E., Benzidia, I., Bertoletti, L., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Farge-Bancel, D., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Schellong, S., Braester, A., Brenner, B., Tzoran, I., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Dentali, F., Di Micco, P., Giammarino, E., Grandone, E., Mangiacapra, S., Mastroiacovo, D., Maida, R., Mumoli, N., Pace, F., Pesavento, R., Pomero, F., Prandoni, P., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Gibietis, V., Kigitovica, D., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Bosevski, M., Zdraveska, M., Bounameaux, H., Mazzolai, L., Caprini, J. A., Tafur, A. J., Wilkins, H., and Bui, H. M.
Subjects: Male, 0301 basic medicine, lcsh:Diseases of the circulatory (Cardiovascular) system, pulmonary embolism, Patient Empowerment, media_common.quotation_subject, 030204 cardiovascular system & hematology, Data Aggregation, 03 medical and health sciences, Presentation, 0302 clinical medicine, thrombosis, pulmonary embolism, risk assessment, Humans, Medicine, Prospective Studies, Registries, cardiovascular diseases, thrombosis, media_common, business.industry, Infographic, risk assessment, Venous Thromboembolism, Hematology, General Medicine, Precision medicine, medicine.disease, Treatment Outcome, 030104 developmental biology, lcsh:RC666-701, Female, Original Article, Aggregate data, Medical emergency, business, Risk assessment, Venous thromboembolism
Abstract: In the current era of patient empowerment and precision medicine, access to timely information is critical to decision-making. Unfortunately, we currently lack patient-specific, real-time data about clinical presentation, risk of thrombotic or hemorrhagic events, key risk factors, and adverse outcomes in patients with venous thromboembolism (VTE). Accordingly, the Registro Informatizado Enfermedad TromboEmbólica (RIETE) investigators developed a tool to provide an open-source, real-time graphic representation of VTE-related data derived from over 90 000 patients with confirmed VTE. This information is intended to facilitate discussion in the informed decision-making process. The current article describes the aims, rationale, methods, and ongoing and future efforts of the real-time VTE infographics developed by the RIETE registry collaborators.
Published: 2020

25. Timing and characteristics of venous thromboembolism after noncancer surgery

Author: Expósito-Ruiz, Manuela, primary, Arcelus, Juan Ignacio, additional, Caprini, Joseph A., additional, López-Espada, Cristina, additional, Bura-Riviere, Alessandra, additional, Amado, Cristina, additional, Loring, Mónica, additional, Mastroiacovo, Daniela, additional, Monreal, Manuel, additional, Prandoni, Paolo, additional, Brenner, Benjamin, additional, Farge-Bancel, Dominique, additional, Barba, Raquel, additional, Di Micco, Pierpaolo, additional, Bertoletti, Laurent, additional, Schellong, Sebastian, additional, Tzoran, Inna, additional, Reis, Abilio, additional, Bosevski, Marijan, additional, Bounameaux, Henri, additional, Malý, Radovan, additional, Verhamme, Peter, additional, Bui, Hanh My, additional, Adarraga, M.D., additional, Agud, M., additional, Aibar, J., additional, Aibar, M.A., additional, Amado, C., additional, Arcelus, J.I., additional, Baeza, C., additional, Ballaz, A., additional, Barba, R., additional, Barbagelata, C., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Blanco-Molina, A., additional, Botella, E., additional, Camon, A.M., additional, Campos, S., additional, Cañas, I., additional, Casado, I., additional, Castro, J., additional, Criado, J., additional, de Ancos, C., additional, de Miguel, J., additional, Toro, J. del, additional, Demelo-Rodríguez, P., additional, Díaz-Pedroche, C., additional, Díaz-Peromingo, J.A., additional, Díez-Sierra, J., additional, Domínguez, I.M., additional, Escribano, J.C., additional, Falgá, C., additional, Farfán, A.I., additional, Fernández de Roitegui, K., additional, Fernández-Aracil, C., additional, Fernández-Capitán, C., additional, Fernández-Reyes, J.L., additional, Fidalgo, M.A., additional, Flores, K., additional, Font, C., additional, Font, L., additional, Francisco, I., additional, Furest, I., additional, Gabara, C., additional, Galeano-Valle, F., additional, García, M.A., additional, García-Bragado, F., additional, García-Hernáez, R., additional, García-Raso, A., additional, Gavín-Sebastián, O., additional, Gil-Díaz, A., additional, Gómez-Cuervo, C., additional, González-Martínez, J., additional, Grau, E., additional, Giménez-Suau, M., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández-Blasco, L., additional, Hernando, E., additional, Herreros, M., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Jiménez, R., additional, Joya, M.D., additional, Jou, I., additional, Lalueza, A., additional, Lecumberri, R., additional, Lima, J., additional, Llamas, P., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Miguel, P., additional, López-Núñez, J.J., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorenzo, A., additional, Loring, M., additional, Madridano, O., additional, Maestre, A., additional, Marchena, P.J., additional, Martín del Pozo, M., additional, Martín-Martos, F., additional, Mella, C., additional, Mellado, M., additional, Mercado, M.I., additional, Moisés, J., additional, Monreal, M., additional, Morales, M.V., additional, Muñoz-Blanco, A., additional, Muñoz-Guglielmetti, D., additional, Muñoz-Rivas, N., additional, Nieto, J.A., additional, Núñez-Ares, A., additional, Núñez-Fernández, M.J., additional, Obispo, B., additional, Olivares, M.C., additional, Orcastegui, J.L., additional, Ortega-Recio, M.D., additional, Osorio, J., additional, Otalora, S., additional, Otero, R., additional, Paredes, D., additional, Parra, P., additional, Parra, V., additional, Pedrajas, J.M., additional, Pellejero, G., additional, Pesántez, D., additional, Porras, J.A., additional, Portillo, J., additional, Riera-Mestre, A., additional, Rivas, A., additional, Rivera, F., additional, Rodríguez-Cobo, A., additional, Rodríguez-Matute, C., additional, Rogado, J., additional, Rosa, V., additional, Rubio, C.M., additional, Ruiz-Artacho, P., additional, Ruiz-Giménez, N., additional, Ruiz-Ruiz, J., additional, Ruiz-Sada, P., additional, Sahuquillo, J.C., additional, Salgueiro, G., additional, Sampériz, A., additional, Sánchez-Muñoz-Torrero, J.F., additional, Sancho, T., additional, Sigüenza, P., additional, Soler, S., additional, Suriñach, J.M., additional, Torres, M.I., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valle, R., additional, Vela, J.R., additional, Vidal, G., additional, Villares, P., additional, Zamora, C., additional, Gutiérrez, P., additional, Vázquez, F.J., additional, Vanassche, T., additional, Vandenbriele, C., additional, Verhamme, P., additional, Hirmerova, J., additional, Malý, R., additional, Benzidia, I., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Crichi, B., additional, Debourdeau, P., additional, Espitia, O., additional, Farge-Bancel, D., additional, Helfer, H., additional, Mahé, I., additional, Moustafa, F., additional, Poenou, G., additional, Schellong, S., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Bilora, F., additional, Brandolin, B., additional, Bucherini, E., additional, Ciammaichella, M., additional, Colaizzo, D., additional, Di Micco, P., additional, Grandone, E., additional, Marchi, D., additional, Mastroiacovo, D., additional, Maida, R., additional, Pace, F., additional, Pesavento, R., additional, Prandoni, P., additional, Quintavalla, R., additional, Rinzivillo, N., additional, Rocci, A., additional, Siniscalchi, C., additional, Tufano, A., additional, Visonà, A., additional, Zalunardo, B., additional, Gibietis, V., additional, Kigitovica, D., additional, Skride, A., additional, Ferreira, M., additional, Fonseca, S., additional, Martins, F., additional, Meireles, J., additional, Bosevski, M., additional, Krstevski, G., additional, Bounameaux, H., additional, Mazzolai, L., additional, Caprini, J.A., additional, Tafur, A.J., additional, Weinberg, I., additional, Wilkins, H., additional, and Bui, H.M., additional
Published: 2021
Full Text: View/download PDF

26. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

Author: Núñez Fernández, Manuel J., primary, Martínez Reglero, Cristina, additional, Nieto Rodríguez, José Antonio, additional, Chouza Piñeiro, Ana, additional, Barcia Sixto, Laura, additional, Maestre Peiró, Ana, additional, Trujillo Santos, Javier, additional, Visonà, Adriana, additional, Fernández-Reyes, José Luis, additional, Monreal Bosch, Manuel, additional, Adarraga, M.D., additional, Agud, M., additional, Aibar, J., additional, Aibar, M.A., additional, Amado, C., additional, Arcelus, J.I., additional, Baeza, C., additional, Ballaz, A., additional, Barba, R., additional, Barbagelata, C., additional, Barrón, M., additional, Barrón-Andrés, B., additional, Bernal, M., additional, Blanco-Molina, A., additional, Botella, E., additional, Camon, A.M., additional, Cañas, I., additional, Casado, I., additional, Castro, J., additional, Chasco, L., additional, Criado, J., additional, de Ancos, C., additional, de Miguel, J., additional, del Toro, J., additional, Demelo-Rodríguez, P., additional, Díaz-Peromingo, J.A., additional, Di Campli, M.V., additional, Díez-Sierra, J., additional, Domínguez, I.M., additional, Encabo, M., additional, Escribano, J.C., additional, Falgá, C., additional, Farfán-Sedano, A.I., additional, Fernández de Roitegui, K., additional, Fernández-Capitán, C., additional, Fernández-Reyes, J.L., additional, Fidalgo, M.A., additional, Flores, K., additional, Font, C., additional, Font, L., additional, Francisco, I., additional, Furest, I., additional, Gabara, C., additional, Galeano-Valle, F., additional, García, M.A., additional, García-Bragado, F., additional, García de Herreros, M., additional, García-Hernáez, R., additional, García-Mullor, M.M., additional, García-Raso, A., additional, Gavín-Sebastián, O., additional, Gil-Díaz, A., additional, Gómez-Cuervo, C., additional, González-Martínez, J., additional, Grau, E., additional, Giménez-Suau, M., additional, Guirado, L., additional, Gutiérrez, J., additional, Hernández-Blasco, L., additional, Hernando, E., additional, Jara-Palomares, L., additional, Jaras, M.J., additional, Jiménez, D., additional, Joya, M.D., additional, Jou, I., additional, Lima, J., additional, Llamas, P., additional, Lobo, J.L., additional, López-Jiménez, L., additional, López-Miguel, P., additional, López-Núñez, J.J., additional, López-Reyes, R., additional, López-Sáez, J.B., additional, Lorenzo, A., additional, Loring, M., additional, Madridano, O., additional, Maestre, A., additional, Marchena, P.J., additional, Martín del Pozo, M., additional, Martín-Martos, F., additional, Mella, C., additional, Mellado, M., additional, Mercado, M.I., additional, Moisés, J., additional, Monreal, M., additional, Morales, M.V., additional, Muñoz-Blanco, A., additional, Muñoz-Guglielmetti, D., additional, Muñoz-Rivas, N., additional, Navas, M.S., additional, Nieto, J.A., additional, Núñez-Ares, A., additional, Núñez-Fernández, M.J., additional, Obispo, B., additional, Olid, M., additional, Olivares, M.C., additional, Orcastegui, J.L., additional, Ortega-Recio, M.D., additional, Osorio, J., additional, Otalora, S., additional, Otero, R., additional, Parra, P., additional, Parra, V., additional, Pedrajas, J.M., additional, Peinado, A., additional, Pellejero, G., additional, Pérez-Jacoiste, A., additional, Porras, J.A., additional, Portillo, J., additional, Riera-Mestre, A., additional, Rivas, A., additional, Rivera, F., additional, Rodríguez-Chiaradía, D.A., additional, Rodríguez-Cobo, A., additional, Rodríguez-Matute, C., additional, Rogado, J., additional, Rojo, R., additional, Rosa, V., additional, Ruiz-Artacho, P., additional, Ruiz-Giménez, N., additional, Ruiz-Ruiz, J., additional, Ruiz-Sada, P., additional, Sahuquillo, J.C., additional, Salgueiro, G., additional, Sampériz, A., additional, Sánchez-Martínez, R., additional, Sánchez-Muñoz-Torrero, J.F., additional, Sancho, T., additional, Soler, S., additional, Suriñach, J.M., additional, Tirado, R., additional, Torres, M.I., additional, Tolosa, C., additional, Trujillo-Santos, J., additional, Uresandi, F., additional, Valero, B., additional, Valle, R., additional, Vela, J.R., additional, Vidal, G., additional, Villares, P., additional, Zamora, C., additional, Gutiérrez, P., additional, Vázquez, F.J., additional, Engelen, M., additional, Vanassche, T., additional, Vehamme, P., additional, Hirmerova, J., additional, Malý, R., additional, Ait Abdallah, N., additional, Bertoletti, L., additional, Bura-Riviere, A., additional, Crichi, B., additional, Debourdeau, P., additional, Espitia, O., additional, Farge-Bancel, D., additional, Helfer, H., additional, Mahé, I., additional, Moustafa, F., additional, Poenou, G., additional, Schellong, S., additional, Braester, A., additional, Brenner, B., additional, Tzoran, I., additional, Bilora, F., additional, Brandolin, B., additional, Bucherini, E., additional, Ciammaichella, M., additional, Colaizzo, D., additional, Di Micco, P., additional, Grandone, E., additional, Imbalzano, E., additional, Maida, R., additional, Mastroiacovo, D., additional, Pace, F., additional, Pesavento, R., additional, Prandoni, P., additional, Quintavalla, R., additional, Rocci, A., additional, Siniscalchi, C., additional, Tufano, A., additional, Visonà, A., additional, Zalunardo, B., additional, Skride, A., additional, Strautmane, S., additional, Zaicenko, A., additional, Ferreira, M., additional, Fonseca, S., additional, Martins, F., additional, Meireles, J., additional, Bosevski, M., additional, Bounameaux, H., additional, Mazzolai, L., additional, Caprini, J.A., additional, Tafur, A.J., additional, Weinberg, I., additional, Wilkins, H., additional, and Bui, H.M., additional
Published: 2020
Full Text: View/download PDF

27. L’an III du DES de médecine vasculaire : l’heure du bilan

Author: Moreau, Y., primary, Tan, S., additional, Bernasconi, M., additional, and Poenou, G., additional
Published: 2020
Full Text: View/download PDF

28. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

Author: Peris, M., Lopez-Nunez, J. J., Maestre, A., Jimenez, D., Muriel, A., Bikdeli, B., Weinberg, I., Ay, C., Mazzolai, L., Lorenzo, A., Monreal, M., Monreel, M., Prandoni, P., Brenner, B., Farge-Bancel, D., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Verhamme, P., Caprini, J. A., Bui, H. M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Aramberri, M., Arcelus, J. I., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Camon, A. M., Canas, I., Cerda, P., Criado, J., de Ancos, C., de Miguel, J., del Toro, J., Demelo-Rodriguez, P., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Diez-Sierra, J., Dominguez, I. M., Encabo, M., Escribano, J. C., Farfan, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., de Roitegui, F. K., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Raso, A., Gavin-Blanco, O., Gavin-Sebastian, O., Gayol, M. C., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Gutierrez, J., Hernandez-Blasco, L., Iglesias, M., Jara-Palomares, L., Jaras, M. J., Joya, M. D., Jou, I., Lacruz, B., Lalueza, A., Lecumberri, R., Lima, J., Llamas, P., Lobo, J. L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Loring, M., Lumbierres, M., Madridano, O., Manrique-Abos, I., Marchena, P. J., Martin-Asenjo, M., Martin-Fernandez, M., Martin-Guerra, J. M., Martin-Martos, F., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Recio, M. D., Osorio, J., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Perez-Ductor, C., Perez-Jacoiste, M. A., Peris, M. L., Pesantez, D., Porras, J. A., Portillo, J., Ramos, E., Reig, L., Riera-Mestre, A., Rivas, A., Rodriguez-Cobo, A., Rodriguez-Fernandez, L., Rodriguez-Galan, I., Rodriguez-Matute, C., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Ruiz-Torregrosa, P., Sahuquillo, J. C., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Sanmartin, R., Soler, S., Suarez, S., Surinach, J. M., Tiberio, G., Tolosa, C., Torres, M. I., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, Vidal, G., Villares, P., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Hirmerova, J., Salgado, E., Benzidia, I., Bura-Riviere, A., Crichi, B., Debourdeau, P., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Braester, A., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Dentali, F., Giammarino, E., Grandone, E., Maida, R., Mangiacapra, S., Mastroiacovo, D., Pace, F., Pesavento, R., Pomero, F., Quintavalla, R., Rocci, A., Siniscalchi, C., Tiraferri, E., Tufano, A., Ventresca, A., Visona, A., Vo Hong, N., Zalunardo, B., Kigitovica, D., Make, K., Skride, A., Ferreira, M., Meireles, J., Zdraveska, M., Tafur, A. J., and Wilkins, H.
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, Mortality rate, Cancer, 030204 cardiovascular system & hematology, medicine.disease, Lower risk, Asymptomatic, Optimal management, Pulmonary embolism, Natural history, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In patient, medicine.symptom, business
Abstract: BackgroundCurrent guidelines suggest treating cancer patients with incidental pulmonary embolism (PE) similarly to those with clinically suspected and confirmed PE. However, the natural history of these presentations has not been thoroughly compared.MethodsWe used the data from the RIETE (Registro Informatizado de Enfermedad TromboEmbólica) registry to compare the 3-month outcomes in patients with active cancer and incidental PE versus those with clinically suspected and confirmed PE. The primary outcome was 90-day all-cause mortality. Secondary outcomes were PE-related mortality, symptomatic PE recurrences and major bleeding.ResultsFrom July 2012 to January 2019, 946 cancer patients with incidental asymptomatic PE and 2274 with clinically suspected and confirmed PE were enrolled. Most patients (95% versus 90%) received low-molecular-weight heparin therapy. During the first 90 days, 598 patients died, including 42 from PE. Patients with incidental PE had a lower all-cause mortality rate than those with suspected and confirmed PE (11% versus 22%; OR 0.43, 95% CI 0.34–0.54). Results were consistent for PE-related mortality (0.3% versus 1.7%; OR 0.18, 95% CI 0.06–0.59). Multivariable analysis confirmed that patients with incidental PE were at lower risk of death (adjusted OR 0.43, 95% CI 0.34–0.56). Overall, 29 (0.9%) patients developed symptomatic PE recurrences, and 122 (3.8%) had major bleeding. There were no significant differences in PE recurrences (OR 0.62, 95% CI 0.25–1.54) or major bleeding (OR 0.78, 95% CI 0.51–1.18).ConclusionsCancer patients with incidental PE had a lower mortality rate than those with clinically suspected and confirmed PE. Further studies are required to validate these findings, and to explore optimal management strategies in these patients.
Published: 2020
Full Text: View/download PDF

29. TEMPORARY REMOVAL: PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?

Author: Petit, B., Soudet, S., Poenou, G., Zarrat, E., Machuron, T., Accassat, S., Plaisance, L., Helfer, H., Mismetti, V., Le Hello, C., Sevestre, M.-A., Mahé, I., and Bertoletti, L.
Subjects: *RANDOMIZED controlled trials, *THROMBOSIS
Abstract: The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. [ABSTRACT FROM AUTHOR]
Published: 2022
Full Text: View/download PDF

30. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

Author: G. Pellejero, Jose Gutierrez, R. Malý, M. Basaglia, L. Chasco, P. Suchon, R. Le Mao, Laurent Bertoletti, F. Martins, J. Caprini, A. Braester, F. Galeano-Valle, Hanh My Bui, J. Alonso, Y. Sato, G. Vidal, Y. Nishimoto, C. Tolosa, E. Nofuentes-Pérez, A.M. Díaz-Brasero, N. Ait Abdallah, M.D. Adarraga, R. Sánchez-Martínez, L. Font, Raquel López-Reyes, Inna Tzoran, Karine Lacut, J. del Toro, Andris Skride, Ana Jaureguizar, Joseph A. Caprini, C. Amado, R. García de la Garza, A.M. Camon, S. Merla, Luciano López-Jiménez, G. Salgueiro, Sebastian Schellong, Alfonso Muriel, F. Bilora, S. Lainez-Justo, B. Suárez-Rodríguez, Carme Font, F. Beddar Chaib, I. Francisco, C. Jiménez-Alfaro, P. Azcarate-Agüero, Maurizio Ciammaichella, J.A. Porras, N. Vo Hong, F. Martín-Martos, Dominique Farge-Bancel, D. Farge-Bancel, José Luis Lobo, M. Giménez-Suau, E. Grau, F. García-Bragado, Ángeles Blanco-Molina, Carmen Fernández-Capitán, María del Carmen Díaz-Pedroche, C. Grange, Adriana Visonà, L. Guirado, P. Villares, P. López-Miguel, José María Pedrajas, S. Accassat, Beatriz Valero, B. Crichi, Juan J. López-Núñez, Luis Jara-Palomares, G. Sarlon-Bartoli, J. Lima, C. Bortoluzzi, Alicia Lorenzo, C. de Ancos, M.A. Fidalgo, Philippe Debourdeau, Pablo Javier Marchena, C. Rodríguez-Matute, A.I. Farfán-Sedano, José Luis Fernández-Reyes, J.C. Escribano, Juan I. Arcelus, M. Barrón, I. Quere, Remedios Otero, A. De Angelis, P. Morange, Peter Verhamme, G. Kenet, P. Prandoni, Pedro Ruiz-Artacho, C. Siniscalchi, A. Zaicenko, M. Olid-Velilla, C. García-Díaz, B. Barrón-Andrés, T. Sancho, Fernando Uresandi, Javier Trujillo-Santos, A. Muñoz-Blanco, A. Villalobos, A. Dubois-Silva, J. Moisés, J. Osorio, M.I. Mercado, J.M. Suriñach, M.A. Aibar, M.D. Joya, Cihan Ay, J.A. Díaz-Peromingo, H. Bounameaux, Diego Martínez-Urbistondo, Thomas Vanassche, L. Bertoletti, Marijan Bosevski, Farès Moustafa, M. Martín del Pozo, J.F. Sánchez-Muñoz-Torrero, H.M. Bui, Ingrid Pabinger, M.C. Olivares, M. García de Herreros, M.J. Núñez-Fernández, B. Zalunardo, J.F. Varona, Stephan Nopp, Behnood Bikdeli, B. Brandolin, B. Bikdeli, Olga Madridano, Manuel Monreal, M.J. Jaras, Alessandra Bura-Rivière, Abílio Reis, J. Portillo, O. Espitia, J. Catella, Aitor Ballaz, F. Esposito, R. Barba, R. Valle, H. Helfer, I. Tzoran, J.B. López-Sáez, P. Ruiz-Artacho, M.A. García, J. Aibar, C. Gómez-Cuervo, C. Gabara, A. Latorre, J. Ruiz-Ruiz, Benjamin Brenner, S. Fonseca, S. Schellong, Raffaele Pesavento, Barry M. Brenner, Silvia Soler, Paolo Prandoni, Victor F. Tapson, Ana Maestre, Pierpaolo Di Micco, M. Muñoz, J. Criado, D. Jiménez, Antonella Tufano, G. Krstevski, B. Valero, Henri Bounameaux, M.I. Torres, G. Poenou, Isabelle Mahé, Aída Gil-Díaz, A. Asuero, S. Otalora, V. Rosa, L. Vela, E. Imbalzano, C. Vandenbriele, C. Barbagelata, Jana Hirmerova, J. Meireles, David Jiménez, Lucia Mazzolai, L. Hernández-Blasco, M. Bosevski, Gili Kenet, C. Mella, M. Monreal, J.R. Vela, P. Di Micco, Carlos Zamora, K. Flores, P. Demelo-Rodríguez, Radovan Malý, J. Birzulis, J.A. Nieto, J. Castro, M.V. Di Campli, Francis Couturaud, Raquel Barba, Jaureguizar, A., Jimenez, D., Bikdeli, B., Ruiz-Artacho, P., Muriel, A., Tapson, V., Lopez-Reyes, R., Valero, B., Kenet, G., Monreal, M., Prandoni, P., Brenner, B., Farge-Bancel, D., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Verhamme, P., Caprini, J. A., Bui, H. M., Adarraga, M. D., Aibar, J., Aibar, M. A., Alonso, J., Amado, C., Arcelus, J. I., Asuero, A., Azcarate-Aguero, P., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Beddar Chaib, F., Camon, A. M., Castro, J., Chasco, L., Criado, J., de Ancos, C., del Toro, J., Demelo-Rodriguez, P., Diaz-Brasero, A. M., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Di Campli, M. V., Dubois-Silva, A., Escribano, J. C., Esposito, F., Farfan-Sedano, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia de Herreros, M., Garcia de la Garza, R., Garcia-Diaz, C., Gil-Diaz, A., Gomez-Cuervo, C., Gimenez-Suau, M., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez-Alfaro, C., Joya, M. D., Lainez-Justo, S., Latorre, A., Lima, J., Lobo, J. L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Saez, J. B., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Urbistondo, D., Mella, C., Mercado, M. I., Moises, J., Munoz, M., Munoz-Blanco, A., Nieto, J. A., Nofuentes-Perez, E., Nunez-Fernandez, M. J., Olid-Velilla, M., Olivares, M. C., Osorio, J., Otalora, S., Otero, R., Pedrajas, J. M., Pellejero, G., Porras, J. A., Portillo, J., Rodriguez-Matute, C., Rosa, V., Ruiz-Ruiz, J., Salgueiro, G., Sanchez-Martinez, R., Sanchez-Munoz-Torrero, J. F., Sancho, T., Soler, S., Suarez-Rodriguez, B., Surinach, J. M., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Varona, J. F., Vela, L., Vela, J. R., Vidal, G., Villalobos, A., Villares, P., Zamora, C., Ay, C., Nopp, S., Pabinger, I., Vanassche, T., Vandenbriele, C., Hirmerova, J., Accassat, S., Ait Abdallah, N., Bura-Riviere, A., Catella, J., Couturaud, F., Crichi, B., Debourdeau, P., Espitia, O., Grange, C., Helfer, H., Lacut, K., Le Mao, R., Mahe, I., Morange, P., Moustafa, F., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Quere, I., Braester, A., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., De Angelis, A., Imbalzano, E., Merla, S., Pesavento, R., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Nishimoto, Y., Sato, Y., Birzulis, J., Skride, A., Zaicenko, A., Fonseca, S., Martins, F., Meireles, J., Krstevski, G., and Mazzolai, L.
Subjects: Male, Registrie, Pulmonary and Respiratory Medicine, medicine.medical_specialty, pulmonary embolism, Critical Care and Intensive Care Medicine, Logistic regression, Heart Rate, Internal medicine, Heart rate, medicine, In patient, Aged, Aged, 80 and over, business.industry, medicine.disease, mortality, Pulmonary embolism, Prospective Studie, Increased risk, Spain, Cardiology, Positive relationship, Female, Cardiology and Cardiovascular Medicine, business, Human
Abstract: Background: The association between heart rate (HR) and pulmonary embolism (PE) outcomes has not been well studied. Furthermore, optimal cutoffs to identify low-risk and intermediate- to high-risk patients are not well known. Research Question: Does an association exist between baseline HR and PE outcome across the continuum of HR values? Study Design and Methods: The current study included 44,331 consecutive nonhypotensive patients with symptomatic PE from the Registro Informatizado de la Enfermedad TromboEmbólica registry between 2001 and 2021. Outcomes included 30-day all-cause and PE-specific mortality. We used hierarchical logistic regression to assess the association between admission HR and outcomes. Results: A positive relationship was found between admission HR and 30-day all-cause and PE-related mortality. Considering an HR of 80 to 99 beats/min as a reference, patients in the higher HR strata showed higher rates of all-cause death (adjusted OR, 1.5 for HR of 100-109 beats/min; adjusted OR, 1.7 for HR of 110-119 beats/min; adjusted OR, 1.9 for HR of 120-139 beats/min; and adjusted OR, 2.4 for HR of ≥ 140 beats/min). Patients in the lower strata of HR showed significantly lower rates of 30-day all-cause mortality compared with the same reference group (adjusted OR, 0.6 for HR of 60-79 beats/min; and adjusted OR, 0.5 for HR of < 60 beats/min). The findings for 30-day PE-related mortality were similar. For identification of low-risk patients, a cutoff value of 80 beats/min (vs 110 beats/min) increased the sensitivity of the simplified Pulmonary Embolism Severity Index (sPESI) from 93.4% to 98.8%. For identification of intermediate- to high-risk patients, a cutoff value of 140 beats/min (vs 110 beats/min) increased the specificity of the Bova score from 93.2% to 98.0%. Interpretation: In nonhypotensive patients with acute symptomatic PE, a high HR portends an increased risk of all-cause and PE-related mortality. Modifying the HR cutoff in the sPESI and the Bova score improves prognostication of patients with PE.
Published: 2022
Full Text: View/download PDF

31. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

Author: Trujillo-Santos J, Farge-Bancel D, Pedrajas JM, Gómez-Cuervo C, Ballaz A, Braester A, Mahé I, Villalobos A, Porras JA, Monreal M, RIETE Investigators, M D Adarraga, J Aibar, M A Aibar, C Amado, J I Arcelus, A Asuero, R Barba, C Barbagelata, M Barrón, B Barrón-Andrés, A Blanco-Molina, E Botella, A M Camon, I Casado, J Castro, M Castro, L Chasco, J Criado, C de Ancos, J Del Toro, P Demelo-Rodríguez, A M Díaz-Brasero, J A Díaz-Peromingo, M V Di Campli, A Dubois-Silva, J C Escribano, F Espósito, C Falgá, A I Farfán-Sedano, C Fernández-Capitán, J L Fernández-Reyes, M A Fidalgo, K Flores, C Font, L Font, I Francisco, C Gabara, F Galeano-Valle, M A García, F García-Bragado, M García de Herreros, R García de la Garza, C García-Díaz, R García-Hernáez, A García-Raso, A Gil-Díaz, M Giménez-Suau, E Grau, L Guirado, J Gutiérrez, L Hernández-Blasco, E Hernando, L Jara-Palomares, M J Jaras, D Jiménez, R Jiménez, C Jiménez-Alfaro, M D Joya, S Lainez-Justo, A Latorre, J Lima, P Llamas, J L Lobo, L López-Jiménez, P López-Miguel, J J López-Núñez, R López-Reyes, J B López-Sáez, A Lorenzo, O Madridano, A Maestre, P J Marchena, F Martín-Martos, D Martínez-Urbistondo, C Mella, M I Mercado, J Moisés, M V Morales, A Muñoz-Blanco, N Muñoz-Rivas, M S Navas, J A Nieto, E Nofuentes-Pérez, M J Núñez-Fernández, B Obispo, M Olid, M C Olivares, J L Orcastegui, J Osorio, S Otalora, R Otero, D Paredes, P Parra, G Pellejero, J Portillo, F Rivera-Civico, D A Rodríguez-Chiaradía, C Rodríguez-Matute, J Rogado, V Rosa, P Ruiz-Artacho, N Ruiz-Giménez, J Ruiz-Ruiz, P Ruiz-Sada, G Salgueiro, R Sánchez-Martínez, J F Sánchez-Muñoz-Torrero, T Sancho, S Soler, B Suárez-Rodríguez, J M Suriñach, R Tirado, M I Torres, C Tolosa, F Uresandi, B Valero, R Valle, J F Varona, G Vidal, P Villares, C Zamora, M Engelen, T Vanassche, P Verhamme, J Hirmerova, R Malý, N Ait Abdallah, L Bertoletti, A Bura-Riviere, J Catella, F Couturaud, B Crichi, P Debourdeau, O Espitia, N Falvo, H Helfer, K Lacut, R Le Mao, F Moustafa, G Poenou, I Quere, S Schellong, B Brenner, I Tzoran, R Nikandish, F Bilora, B Brandolin, M Ciammaichella, P Di Micco, E Imbalzano, R Maida, F Pace, R Pesavento, P Prandoni, R Quintavalla, A Rocci, C Siniscalchi, A Tufano, A Visonà, B Zalunardo, J Birzulis, A Skride, A Zaicenko, S Fonseca, F Martins, J Meireles, M Bosevski, H Bounameaux, L Mazzolai, C I Ochoa-Chaar, I Weinberg, H M Bui, J, Trujillo-Santo, D, Farge-Bancel, Jm, Pedraja, C, Gómez-Cuervo, A, Ballaz, A, Braester, I, Mahé, A, Villalobo, Ja, Porra, M, Monreal, Investigators, Riete, D Adarraga, M, Aibar, J, A Aibar, M, Amado, C, I Arcelus, J, Asuero, A, Barba, R, Barbagelata, C, Barrón, M, Barrón-Andrés, B, Blanco-Molina, A, Botella, E, M Camon, A, Casado, I, Castro, J, Castro, M, Chasco, L, Criado, J, de Ancos, C, Del Toro, J, Demelo-Rodríguez, P, M Díaz-Brasero, A, A Díaz-Peromingo, J, V Di Campli, M, Dubois-Silva, A, C Escribano, J, Espósito, F, Falgá, C, I Farfán-Sedano, A, Fernández-Capitán, C, L Fernández-Reyes, J, A Fidalgo, M, Flores, K, Font, C, Font, L, Francisco, I, Gabara, C, Galeano-Valle, F, A García, M, García-Bragado, F, García de Herreros, M, García de la Garza, R, García-Díaz, C, García-Hernáez, R, García-Raso, A, Gil-Díaz, A, Giménez-Suau, M, Grau, E, Guirado, L, Gutiérrez, J, Hernández-Blasco, L, Hernando, E, Jara-Palomares, L, J Jaras, M, Jiménez, D, Jiménez, R, Jiménez-Alfaro, C, D Joya, M, Lainez-Justo, S, Latorre, A, Lima, J, Llamas, P, L Lobo, J, López-Jiménez, L, López-Miguel, P, J López-Núñez, J, López-Reyes, R, B López-Sáez, J, Lorenzo, A, Madridano, O, Maestre, A, J Marchena, P, Martín-Martos, F, Martínez-Urbistondo, D, Mella, C, I Mercado, M, Moisés, J, V Morales, M, Muñoz-Blanco, A, Muñoz-Rivas, N, S Navas, M, A Nieto, J, Nofuentes-Pérez, E, J Núñez-Fernández, M, Obispo, B, Olid, M, C Olivares, M, L Orcastegui, J, Osorio, J, Otalora, S, Otero, R, Paredes, D, Parra, P, Pellejero, G, Portillo, J, Rivera-Civico, F, A Rodríguez-Chiaradía, D, Rodríguez-Matute, C, Rogado, J, Rosa, V, Ruiz-Artacho, P, Ruiz-Giménez, N, Ruiz-Ruiz, J, Ruiz-Sada, P, Salgueiro, G, Sánchez-Martínez, R, F Sánchez-Muñoz-Torrero, J, Sancho, T, Soler, S, Suárez-Rodríguez, B, M Suriñach, J, Tirado, R, I Torres, M, Tolosa, C, Uresandi, F, Valero, B, Valle, R, F Varona, J, Vidal, G, Villares, P, Zamora, C, Engelen, M, Vanassche, T, Verhamme, P, Hirmerova, J, Malý, R, Ait Abdallah, N, Bertoletti, L, Bura-Riviere, A, Catella, J, Couturaud, F, Crichi, B, Debourdeau, P, Espitia, O, Falvo, N, Helfer, H, Lacut, K, Le Mao, R, Moustafa, F, Poenou, G, Quere, I, Schellong, S, Brenner, B, Tzoran, I, Nikandish, R, Bilora, F, Brandolin, B, Ciammaichella, M, Di Micco, P, Imbalzano, E, Maida, R, Pace, F, Pesavento, R, Prandoni, P, Quintavalla, R, Rocci, A, Siniscalchi, C, Tufano, A, Visonà, A, Zalunardo, B, Birzulis, J, Skride, A, Zaicenko, A, Fonseca, S, Martins, F, Meireles, J, Bosevski, M, Bounameaux, H, Mazzolai, L, I Ochoa-Chaar, C, Weinberg, I, and M Bui, H
Subjects: dalteparin, recurrences, tinzaparin, venous thromboembolism, cancer, enoxaparin, Hematology, cohort, LMWH
Abstract: Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. The objective of the RIETECAT study was to compare the long-term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondary prevention of VTE in adults with active cancer. We used the data from the multicenter, multinational RIETE registry to compare the rates of VTE recurrences, major bleeding, or death over 6 months in patients with active cancer and acute VTE using full doses of enoxaparin versus dalteparin or tinzaparin, and a multivariable Cox proportional hazard model was used to analyze the primary end point. From January 2009 to June 2018, 4451 patients with active cancer received full doses of the study drugs: enoxaparin, 3526 patients; and dalteparin or tinzaparin, 925 (754 + 171) patients. There was limited difference in VTE recurrences (2.0% vs 2.5%) and mortality rate (19% vs 17%) between the enoxaparin and dalteparin or tinzaparin subgroups. However, there was a slight numerical increase in major bleeding (3.1% vs 1.9%). Propensity score matching confirmed that there were no differences in the risk for VTE recurrences (adjusted hazard ratio [aHR], 0.81; 95% confidence interval [CI], 0.48-1.38), major bleeding (aHR, 1.40; 95% CI, 0.80-2.46), or death (aHR, 1.07; 95% CI, 0.88-1.30) between subgroups. In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.
Published: 2022

32. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

Author: Marc Blondon, David Jimenez, Helia Robert‐Ebadi, Jorge Del Toro, Luciano Lopez‐Jimenez, Conxita Falga, Andris Skride, Llorenç Font, Fernando Javier Vazquez, Henri Bounameaux, Manuel Monreal, Paolo Prandoni, Benjamin Brenner, Dominique Farge‐Bancel, Raquel Barba, Pierpaolo Di Micco, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Abilio Reis, Marijan Bosevski, Radovan Malý, Peter Verhamme, Joseph A Caprini, Hanh My Bui, MD Adarraga, M Agud, J Aibar, MA Aibar, J Alfonso, C Amado, JI Arcelus, C Baeza, A Ballaz, R Barba, C Barbagelata, M Barrón, B Barrón‐Andrés, A Blanco‐Molina, E Botella, AM Camon, J Castro, MA Caudevilla, P Cerdà, L Chasco, J Criado, C de Ancos, J de Miguel, P Demelo‐Rodríguez, JA Díaz‐Peromingo, J Díez‐Sierra, R Díaz‐Simón, IM Domínguez, M Encabo, JC Escribano, C Falgá, AI Farfán, C Fernández‐Capitán, JL Fernández‐Reyes, MA Fidalgo, K Flores, C Font, I Francisco, C Gabara, F Galeano‐Valle, MA García, F García‐Bragado, MM García‐Mullor, O Gavín‐Blanco, O Gavín‐Sebastián, A Gil‐Díaz, C Gómez‐Cuervo, J González‐Martínez, E Grau, L Guirado, J Gutiérrez, L Hernández‐Blasco, L Jara‐Palomares, MJ Jaras, D Jiménez, MD Joya, I Jou, B Lacruz, R Lecumberri, J Lima, JL Lobo, H López‐Brull, L López‐Jiménez, P López‐Miguel, JJ López‐Núñez, R López‐Reyes, JB López‐Sáez, MA Lorente, A Lorenzo, M Loring, O Madridano, A Maestre, PJ Marchena, M Martín del Pozo, F Martín‐Martos, C Martínez‐Baquerizo, C Mella, M Mellado, MI Mercado, J Moisés, MV Morales, A Muñoz‐Blanco, D Muñoz‐Guglielmetti, N Muñoz‐Rivas, E Nart, JA Nieto, MJ Núñez, MC Olivares, C Ortega‐Michel, MD Ortega‐Recio, J Osorio, S Otalora, R Otero, P Parra, V Parra, JM Pedrajas, G Pellejero, A Pérez‐Jacoiste, ML Peris, D Pesántez, JA Porras, J Portillo, L Reig, A Riera‐Mestre, A Rivas, A Rodríguez‐Cobo, C Rodríguez‐Matute, J Rogado, V Rosa, CM Rubio, P Ruiz‐Artacho, N Ruiz‐Giménez, J Ruiz‐Ruiz, P Ruiz‐Sada, JC Sahuquillo, G Salgueiro, A Sampériz, JF Sánchez‐Muñoz‐Torrero, T Sancho, P Sigüenza, M Sirisi, S Soler, S Suárez, JM Suriñach, G Tiberio, MI Torres, C Tolosa, J Trujillo‐Santos, F Uresandi, E Usandizaga, R Valle, JR Vela, G Vidal, C Vilar, P Villares, C Zamora, P Gutiérrez, FJ Vázquez, T Vanassche, C Vandenbriele, P Verhamme, J Hirmerova, R Malý, E Salgado, I Benzidia, L Bertoletti, A Bura‐Riviere, B Crichi, P Debourdeau, O Espitia, D Farge‐Bancel, H Helfer, I Mahé, F Moustafa, G Poenou, S Schellong, A Braester, B Brenner, I Tzoran, M Amitrano, F Bilora, C Bortoluzzi, B Brandolin, M Ciammaichella, D Colaizzo, F Dentali, P Di Micco, E Giammarino, E Grandone, S Mangiacapra, D Mastroiacovo, R Maida, N Mumoli, F Pace, R Pesavento, F Pomero, P Prandoni, R Quintavalla, A Rocci, C Siniscalchi, A Tufano, A Visonà, N Vo Hong, B Zalunardo, RV Kalejs, K Maķe, M Ferreira, S Fonseca, F Martins, J Meireles, M Bosevski, M Zdraveska, L Mazzolai, JA Caprini, AJ Tafur, I Weinberg, H Wilkins, HM Bui, Blondon, M., Jimenez, D., Robert-Ebadi, H., Del Toro, J., Lopez-Jimenez, L., Falga, C., Skride, A., Font, L., Vazquez, F. J., Bounameaux, H., Monreal, M., Prandoni, P., Brenner, B., Farge-Bancel, D., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Maly, R., Verhamme, P., Caprini, J. A., My Bui, H., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Alfonso, J., Amado, C., Arcelus, J. I., Baeza, C., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Botella, E., Camon, A. M., Castro, J., Caudevilla, M. A., Cerda, P., Chasco, L., Criado, J., de Ancos, C., de Miguel, J., Demelo-Rodriguez, P., Diaz-Peromingo, J. A., Diez-Sierra, J., Diaz-Simon, R., Dominguez, I. M., Encabo, M., Escribano, J. C., Farfan, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Mullor, M. M., Gavin-Blanco, O., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Joya, M. D., Jou, I., Lacruz, B., Lecumberri, R., Lima, J., Lobo, J. L., Lopez-Brull, H., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorente, M. A., Lorenzo, A., Loring, M., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Baquerizo, C., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Munoz-Rivas, N., Nart, E., Nieto, J. A., Nunez, M. J., Olivares, M. C., Ortega-Michel, C., Ortega-Recio, M. D., Osorio, J., Otalora, S., Otero, R., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Perez-Jacoiste, A., Peris, M. L., Pesantez, D., Porras, J. A., Portillo, J., Reig, L., Riera-Mestre, A., Rivas, A., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rogado, J., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J. C., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Siguenza, P., Sirisi, M., Soler, S., Suarez, S., Surinach, J. M., Tiberio, G., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Usandizaga, E., Valle, R., Vela, J. R., Vidal, G., Vilar, C., Villares, P., Zamora, C., Gutierrez, P., Vanassche, T., Vandenbriele, C., Hirmerova, J., Salgado, E., Benzidia, I., Bura-Riviere, A., Crichi, B., Debourdeau, P., Espitia, O., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Braester, A., Amitrano, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., Colaizzo, D., Dentali, F., Giammarino, E., Grandone, E., Mangiacapra, S., Mastroiacovo, D., Maida, R., Mumoli, N., Pace, F., Pesavento, R., Pomero, F., Quintavalla, R., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Kalejs, R. V., Maie, K., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Zdraveska, M., Mazzolai, L., Tafur, A. J., Weinberg, I., Wilkins, H., and Bui, H. M.
Subjects: Registrie, medicine.medical_specialty, pulmonary embolism, Prognosi, Hemodynamics, 030204 cardiovascular system & hematology, Cohort Studies, 03 medical and health sciences, Clinical prognosis, 0302 clinical medicine, Recurrence, Internal medicine, Case fatality rate, medicine, Humans, hemorrhage, mortality, prognosis, thrombolytic therapy, Registries, cardiovascular diseases, business.industry, Anticoagulant, Anticoagulants, Hematology, Venous Thromboembolism, Prognosis, medicine.disease, Confidence interval, Pulmonary embolism, Discontinuation, Cohort Studie, business, Venous thromboembolism, Cohort study, Human
Abstract: Aims Little is known about the prognosis of patients with massive pulmonary embolism (PE) and its risk of recurrent venous thromboembolism (VTE) compared with non-massive PE, which may inform clinical decisions. Our aim was to compare the risk of recurrent VTE, bleeding, and mortality after massive and non-massive PE during anticoagulation and after its discontinuation. Methods and results We included all participants in the RIETE registry who suffered a symptomatic, objectively confirmed segmental or more central PE. Massive PE was defined by a systolic hypotension at clinical presentation (
Published: 2021

33. Timing and characteristics of venous thromboembolism after noncancer surgery

Author: Manuela Expósito-Ruiz, Juan Ignacio Arcelus, Joseph A. Caprini, Cristina López-Espada, Alessandra Bura-Riviere, Cristina Amado, Mónica Loring, Daniela Mastroiacovo, Manuel Monreal, Paolo Prandoni, Benjamin Brenner, Dominique Farge-Bancel, Raquel Barba, Pierpaolo Di Micco, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Abilio Reis, Marijan Bosevski, Henri Bounameaux, Radovan Malý, Peter Verhamme, Hanh My Bui, M.D. Adarraga, M. Agud, J. Aibar, M.A. Aibar, C. Amado, J.I. Arcelus, C. Baeza, A. Ballaz, R. Barba, C. Barbagelata, M. Barrón, B. Barrón-Andrés, A. Blanco-Molina, E. Botella, A.M. Camon, S. Campos, I. Cañas, I. Casado, J. Castro, J. Criado, C. de Ancos, J. de Miguel, J. del Toro, P. Demelo-Rodríguez, C. Díaz-Pedroche, J.A. Díaz-Peromingo, J. Díez-Sierra, I.M. Domínguez, J.C. Escribano, C. Falgá, A.I. Farfán, K. Fernández de Roitegui, C. Fernández-Aracil, C. Fernández-Capitán, J.L. Fernández-Reyes, M.A. Fidalgo, K. Flores, C. Font, L. Font, I. Francisco, I. Furest, C. Gabara, F. Galeano-Valle, M.A. García, F. García-Bragado, R. García-Hernáez, A. García-Raso, O. Gavín-Sebastián, A. Gil-Díaz, C. Gómez-Cuervo, J. González-Martínez, E. Grau, M. Giménez-Suau, L. Guirado, J. Gutiérrez, L. Hernández-Blasco, E. Hernando, M. Herreros, L. Jara-Palomares, M.J. Jaras, D. Jiménez, R. Jiménez, M.D. Joya, I. Jou, A. Lalueza, R. Lecumberri, J. Lima, P. Llamas, J.L. Lobo, L. López-Jiménez, P. López-Miguel, J.J. López-Núñez, R. López-Reyes, J.B. López-Sáez, A. Lorenzo, M. Loring, O. Madridano, A. Maestre, P.J. Marchena, M. Martín del Pozo, F. Martín-Martos, C. Mella, M. Mellado, M.I. Mercado, J. Moisés, M. Monreal, M.V. Morales, A. Muñoz-Blanco, D. Muñoz-Guglielmetti, N. Muñoz-Rivas, J.A. Nieto, A. Núñez-Ares, M.J. Núñez-Fernández, B. Obispo, M.C. Olivares, J.L. Orcastegui, M.D. Ortega-Recio, J. Osorio, S. Otalora, R. Otero, D. Paredes, P. Parra, V. Parra, J.M. Pedrajas, G. Pellejero, D. Pesántez, J.A. Porras, J. Portillo, A. Riera-Mestre, A. Rivas, F. Rivera, A. Rodríguez-Cobo, C. Rodríguez-Matute, J. Rogado, V. Rosa, C.M. Rubio, P. Ruiz-Artacho, N. Ruiz-Giménez, J. Ruiz-Ruiz, P. Ruiz-Sada, J.C. Sahuquillo, G. Salgueiro, A. Sampériz, J.F. Sánchez-Muñoz-Torrero, T. Sancho, P. Sigüenza, S. Soler, J.M. Suriñach, M.I. Torres, C. Tolosa, J. Trujillo-Santos, F. Uresandi, R. Valle, J.R. Vela, G. Vidal, P. Villares, C. Zamora, P. Gutiérrez, F.J. Vázquez, T. Vanassche, C. Vandenbriele, P. Verhamme, J. Hirmerova, R. Malý, I. Benzidia, L. Bertoletti, A. Bura-Riviere, B. Crichi, P. Debourdeau, O. Espitia, D. Farge-Bancel, H. Helfer, I. Mahé, F. Moustafa, G. Poenou, S. Schellong, A. Braester, B. Brenner, I. Tzoran, F. Bilora, B. Brandolin, E. Bucherini, M. Ciammaichella, D. Colaizzo, P. Di Micco, E. Grandone, D. Marchi, D. Mastroiacovo, R. Maida, F. Pace, R. Pesavento, P. Prandoni, R. Quintavalla, N. Rinzivillo, A. Rocci, C. Siniscalchi, A. Tufano, A. Visonà, B. Zalunardo, V. Gibietis, D. Kigitovica, A. Skride, M. Ferreira, S. Fonseca, F. Martins, J. Meireles, M. Bosevski, G. Krstevski, H. Bounameaux, L. Mazzolai, J.A. Caprini, A.J. Tafur, I. Weinberg, H. Wilkins, H.M. Bui, Exposito-Ruiz, M., Arcelus, J. I., Caprini, J. A., Lopez-Espada, C., Bura-Riviere, A., Amado, C., Loring, M., Mastroiacovo, D., Monreal, M., Prandoni, P., Brenner, B., Farge-Bancel, D., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Verhamme, P., Bui, H. M., Adarraga, M. D., Agud, M., Aibar, J., Aibar, M. A., Baeza, C., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Botella, E., Camon, A. M., Campos, S., Canas, I., Casado, I., Castro, J., Criado, J., de Ancos, C., de Miguel, J., Toro, J. D., Demelo-Rodriguez, P., Diaz-Pedroche, C., Diaz-Peromingo, J. A., Diez-Sierra, J., Dominguez, I. M., Escribano, J. C., Falga, C., Farfan, A. I., Fernandez de Roitegui, K., Fernandez-Aracil, C., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Furest, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia-Hernaez, R., Garcia-Raso, A., Gavin-Sebastian, O., Gil-Diaz, A., Gomez-Cuervo, C., Gonzalez-Martinez, J., Grau, E., Gimenez-Suau, M., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Hernando, E., Herreros, M., Jara-Palomares, L., Jaras, M. J., Jimenez, D., Jimenez, R., Joya, M. D., Jou, I., Lalueza, A., Lecumberri, R., Lima, J., Llamas, P., Lobo, J. L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Reyes, R., Lopez-Saez, J. B., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Mella, C., Mellado, M., Mercado, M. I., Moises, J., Morales, M. V., Munoz-Blanco, A., Munoz-Guglielmetti, D., Munoz-Rivas, N., Nieto, J. A., Nunez-Ares, A., Nunez-Fernandez, M. J., Obispo, B., Olivares, M. C., Orcastegui, J. L., Ortega-Recio, M. D., Osorio, J., Otalora, S., Otero, R., Paredes, D., Parra, P., Parra, V., Pedrajas, J. M., Pellejero, G., Pesantez, D., Porras, J. A., Portillo, J., Riera-Mestre, A., Rivas, A., Rivera, F., Rodriguez-Cobo, A., Rodriguez-Matute, C., Rogado, J., Rosa, V., Rubio, C. M., Ruiz-Artacho, P., Ruiz-Gimenez, N., Ruiz-Ruiz, J., Ruiz-Sada, P., Sahuquillo, J. C., Salgueiro, G., Samperiz, A., Sanchez-Munoz-Torrero, J. F., Sancho, T., Siguenza, P., Soler, S., Surinach, J. M., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Vela, J. R., Vidal, G., Villares, P., Zamora, C., Gutierrez, P., Vazquez, F. J., Vanassche, T., Vandenbriele, C., Hirmerova, J., Benzidia, I., Crichi, B., Debourdeau, P., Espitia, O., Helfer, H., Mahe, I., Moustafa, F., Poenou, G., Braester, A., Bilora, F., Brandolin, B., Bucherini, E., Ciammaichella, M., Colaizzo, D., Grandone, E., Marchi, D., Maida, R., Pace, F., Pesavento, R., Quintavalla, R., Rinzivillo, N., Rocci, A., Siniscalchi, C., Tufano, A., Visona, A., Zalunardo, B., Gibietis, V., Kigitovica, D., Skride, A., Ferreira, M., Fonseca, S., Martins, F., Meireles, J., Krstevski, G., Mazzolai, L., Tafur, A. J., Weinberg, I., and Wilkins, H.
Subjects: Adult, Male, Registrie, medicine.medical_specialty, Time Factors, Time Factor, Duration of risk, 030204 cardiovascular system & hematology, Drug Administration Schedule, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, Risk Factors, Deep vein thrombosi, Interquartile range, medicine, Humans, Registries, cardiovascular diseases, 030212 general & internal medicine, Aged, Venous Thrombosis, Benign disease, business.industry, Risk Factor, Incidence (epidemiology), Pulmonary embolism, Anticoagulant, Anticoagulants, Venous Thromboembolism, Heparin, Low-Molecular-Weight, Middle Aged, equipment and supplies, medicine.disease, Thrombosis, Surgery, Time course, Thromboprophylaxi, Female, Postoperative Complication, Cardiology and Cardiovascular Medicine, business, Venous thromboembolism, Human, Surgical patients
Abstract: Background Venous thromboembolism (VTE) is a major cause of morbidity and mortality postoperatively. The use of pharmacologic prophylaxis is effective in reducing the incidence of VTE. However, the prophylaxis is often discontinued at hospital discharge, especially for those with benign disease. The implications of this practice are not known. We assessed the data from a large, ongoing registry regarding the time course of VTE and outcomes after noncancer surgery. Methods We analyzed the RIETE (Computerized Registry on Venous Thromboembolism) registry, which includes data from consecutive patients with symptomatic confirmed VTE. In the present study, we focused on general surgical patients who had developed symptomatic postoperative VTE in the first 8 weeks after noncancer surgery. The main objective was to assess the interval between surgery and the occurrence of VTE. Additional variables included the clinical presentation associated with the event, the use of thrombosis prophylaxis, and unfavorable outcomes. Results The data from 3296 patients were analyzed. The median time from surgery to the detection of VTE was 16 days (interquartile range, 8-30 days). Of the VTE events, 77% were detected after the first postoperative week and 27% after 4 weeks. Overall, 43.9% of the patients with VTE had received pharmacologic prophylaxis after surgery for a median of 8 days (interquartile range, 5-14 days), and three quarters of the VTE events were detected after pharmacologic prophylaxis had been discontinued. Overall, 54% of the patients with VTE had presented with pulmonary embolism. For 15% of the patients, the clinical outcome was unfavorable, including 4% who had died within 90 days. Conclusions The risk of VTE after noncancer general surgery remains high for ≤2 months. More than one half of the patients had presented with symptomatic PE as the VTE event, and 15% had had unfavorable outcomes. Only 44% of these patients had received pharmacologic prophylaxis for around 1 week.
Published: 2021
Full Text: View/download PDF

34. Venous thromboembolism in patients aged ≥90 years: Trends in clinical features, treatment, and outcomes-RIETE registry.

Author: Lafaie L, Poenou G, Hanon O, Otálora S, Jiménez LL, Ballaz A, Soler S, Fernández MJN, Bertoletti L, and Monreal M
Abstract: Background: Data on patients aged 90 or older are rare. This study aims to describe clinical characteristics, treatment strategies, and clinical outcomes (rates of VTE recurrence, major bleeding, and mortality), during the first 3 months of anticoagulant treatment for VTE, depending on the treatment period., Methods: We analyzed data from RIETE, an ongoing global observational registry of patients with objectively confirmed acute VTE, grouped in 5-year intervals (2004-2008, 2009-2013, 2014-2018, and 2019-2023)., Results: Among 3477 patients aged 90 or older, clinical characteristics have changed over time (less heart failure, more dementia), with an increase in PE diagnoses from 57% in 2004-2008 to 69% in 2019-2023 (p-trends <0.001), but of lower severity. For long-term therapy, there was an increase in patients receiving DOACs (p-trends <0.001), with a decrease in patients on VKAs (p-trends <0.001). Mortality and fatal PE respectively showed a temporal trend: 19% and 4% in 2004-2008 to 15% (p-trends 0.026) and 2% (p-trends 0.002) in 2019-2023. In multivariable analyses, fatal PE declined from 2004 to 2023 (HR: 0.91; 95% CI: 0.87-0.96). Compared with VKAs, receiving LMWH during the first 3 months of anticoagulation was associated with a higher risk of major bleeding (HR: 1.91; 95% CI: 1.16-3.14) and death (HR: 2.20; 95% CI: 1.71-2.82). The effect seems to be the opposite for DOACs (HR: 0.50; 95% CI: 0.20-1.30 for major bleeding; HR: 0.86; 95% CI: 0.57-1.28 for all-cause death)., Conclusions: Fatal PE declined from 2004 to 2023, despite an increase in the diagnosis of PE. Since the arrival of DOACs, there seems to be better management of the therapeutic and diagnostic aspects of VTE in this population, underlining the need for further research on patients aged 90 or older., (© 2024 The American Geriatrics Society.)
Published: 2024
Full Text: View/download PDF

35. Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH.

Author: Escal J, Poenou G, Delavenne X, Bezzeghoud S, Mismetti V, Humbert M, Montani D, and Bertoletti L
Subjects: Humans, Administration, Oral, Disease Management, Drug Interactions, Drug Therapy, Combination, Vitamin K antagonists & inhibitors, Anticoagulants therapeutic use, Anticoagulants administration & dosage, Hypertension, Pulmonary drug therapy, Pulmonary Arterial Hypertension drug therapy, Pulmonary Embolism drug therapy
Abstract: The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) presents distinct therapeutic challenges and benefits. In PAH, the benefits of oral anticoagulation are uncertain, with studies yielding mixed results on their efficacy and safety. Conversely, oral anticoagulants are a cornerstone in the treatment of CTEPH, where their use is consistently recommended to prevent recurrent thromboembolic events. The choice between vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) remains a significant clinical question, as each type presents advantages and potential drawbacks. Furthermore, drug-drug interactions (DDIs) with concomitant PAH and CTEPH treatments complicate anticoagulant management, necessitating careful consideration of individual patient regimens. This review examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of DDIs within a context of multi-drug treatments, including targeted drugs in PAH., Competing Interests: Declaration of competing interest No conflicts to disclose., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
Published: 2024
Full Text: View/download PDF

36. Venous Thromboembolism after Hospital Discharge: Temporal Trends in Baseline Characteristics, Prevention, Treatment, and 90-day Outcomes.

Author: Brenner B, Tzoran I, Bikdeli B, Valle R, Poenou G, Tirado-Miranda R, Pesce ML, Pagán-Escribano J, Giorgi-Pierfranceschi M, and Monreal M
Abstract: Venous thromboembolism (VTE) after hospital discharge poses a serious health risk. Assessments of patient characteristics, prophylaxis, treatment, outcomes, and over time changes lack consistency. Data on 16,901 hospitalized patients in the Registro Informatizado Enfermedad TromboEmbolica registry (2003-2022) were analyzed to evaluate trends in baseline characteristics, prophylaxis, treatments, and 90-day outcomes among medical (6,218) and surgical (10,683) patient cohorts. Multivariable logistic regression was used to assess the risks of the composite of fatal pulmonary embolism (PE) or recurrent VTE and major bleeding. The proportion of patients who presented with PE increased among medical (from 54 to 72%) and surgical patients (from 55 to 58%). Prophylaxis use increased in medical patients (from 53 to 71%), while decreasing in surgical patients (from 67 to 58%). Notably, the 90-day composite of fatal PE or recurrent VTE decreased in medical (from 3.9 to 1.8%) and surgical patients (from 2.9 to 1.2%; p < 0.001 for both). Conversely, major bleeding increased (3.1 to 4.5%) in medical patients ( p = 0.008), with no change in surgical patients (from 2.5 to 2.4%). Risk-adjusted analysis showed a yearly decrease in the risk for the composite outcome (subhazard ratio [sHR]: 0.95; 95% confidence interval [CI]: 0.93-0.98) in medical and surgical patients and an increase in the risk for major bleeding in medical patients only (sHR: 1.04; 95% CI: 1.01-1.07). Results were consistent after excluding coronavirus disease 2019 patients. Over 20 years, the composite of fatal PE or recurrent VTE within 90 days had significantly decreased in VTE patients after hospitalization for medical or surgical care. Medical patients, however, exhibited an increase in major bleeding., Competing Interests: B.B. declares receiving honoraria for lectures and advisory board contributions from Sanofi, ROVI Laboratories, Johnson & Johnson, and HORIBA Medical. B.B. is supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814). B.B. was supported by the Scott Schoen and Nancy Adams IGNITE Award and is supported by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital, and the Heart and Vascular Center Junior Faculty Award from Brigham and Women's Hospital. B.B. reports that he was a consulting expert, on behalf of the plaintiff, for litigation related to two specific brand models of inferior vena cava (IVC) filters. B.B. has not been involved in the litigation in 2022 to 2024 nor has he received any compensation in 2022 to 2024. B.B. reports that he is a member of the Medical Advisory Board for the North American Thrombosis Forum and serves in the Data Safety and Monitory Board of the NAIL-IT trial funded by the National Heart, Lung, and Blood Institute, and Translational Sciences. B.B. is a collaborating consultant with the International Consulting Associates and the U.S. Food and Drug Administration in a study to generate knowledge about utilization, predictors, retrieval, and safety of IVC filters. Other authors disclose no potential conflict of interest., (Thieme. All rights reserved.)
Published: 2024
Full Text: View/download PDF

37. Latest advances in the reversal strategies for direct oral anticoagulants.

Author: Escal J, Lanoiselée J, Poenou G, Zufferey P, Laporte S, Mismetti P, and Delavenne X
Subjects: Humans, Administration, Oral, Thrombosis prevention & control, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized adverse effects, Factor Xa Inhibitors adverse effects, Factor Xa Inhibitors administration & dosage, Factor Xa Inhibitors pharmacology, Recombinant Proteins administration & dosage, Factor Xa, Anticoagulants adverse effects, Anticoagulants administration & dosage, Anticoagulants pharmacology, Anticoagulants therapeutic use, Antidotes therapeutic use, Antidotes administration & dosage, Hemorrhage chemically induced
Abstract: Background: Since the late 2000s, Europe has granted approval for various thrombotic risk-related uses of direct oral anticoagulants (DOACs). Unlike traditional anticoagulants, DOACs do not necessitate routine coagulation monitoring. Nevertheless, clinical practice often encounters bleeding events associated with these medications, making the need for effective reversal strategies evident., Objectives: The study aims to take stock of current reversal strategies for DOACs, with a particular emphasis on the latest compounds that have been developed or are currently under development., Methods: For obtaining information regarding the ongoing reversal strategies and the compounds under development, we referred to ClinicalTrials website, PubMed, and Google Scholar., Results: In 2024, two specific antidotes to DOACs have already received approval when reversal of anticoagulation is needed owing to life-threatening or uncontrolled bleeding: idarucizumab that reverses the effects of dabigatran, and andexanet alfa, designed to counteract activated factor X inhibitors such as apixaban and rivaroxaban. Furthermore, ciraparantag, a potential universal reversal agent, is currently in advanced stages of clinical development. Concerns remain regarding the safety of specific reversal agents, especially concerning the risk of thrombosis. Additionally, the cost of these antidotes remains high. Consequently, nonspecific strategies to counteract anticoagulant medications, including activated charcoal, hemodialysis, and concentrates of coagulation factors, still have utility., Conclusion: With the validation of specific and nonspecific antidotes, DOACs could supplant traditional oral anticoagulants. This progress represents a significant advancement in anticoagulation therapy. However, ongoing research is crucial to address remaining safety concerns of the specific reversion agents of DOACs in clinical practice., (© 2024 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.)
Published: 2024
Full Text: View/download PDF

38. Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors.

Author: Schreuder M, Jourdi G, Veizaj D, Poole DA 3rd, Cheung KL, Poenou G, Verhoef D, Thomassen S, Janssen LFH, Stepanian A, Hackeng TM, Gaussem P, Reitsma PH, Geerke DP, Siguret V, and Bos MHA
Subjects: Humans, HEK293 Cells, Factor Xa metabolism, Pyridines therapeutic use, Pyridines pharmacology, Molecular Dynamics Simulation, Thiazoles pharmacology, Thrombin metabolism, Thrombin chemistry, Hemorrhage, Protein Binding, Factor Xa Inhibitors pharmacology, Rivaroxaban, Blood Coagulation drug effects, Pyrazoles pharmacology, Factor X metabolism, Pyridones pharmacology
Abstract: Background: Direct oral factor (F)Xa inhibitors are widely used as alternatives to conventional vitamin K antagonists in managing venous thromboembolism and nonvalvular atrial fibrillation. Unfortunately, bleeding-related adverse events remain a major concern in clinical practice. In case of bleeding or emergency surgery, rapid-onset reversal agents may be required to counteract the anticoagulant activity., Objectives: The ability of FXa variants to bypass the direct oral FXa inhibitors was assessed., Methods: Human FXa variants were generated through substitution of phenylalanine 174 (F174) for either alanine, isoleucine, or serine. FXa variants were stably expressed in HEK293 cells and purified to homogeneity using ion-exchange chromatography., Results: F174-substituted human FX variants demonstrated efficacy in restoring thrombin generation in plasma containing direct FXa inhibitors (apixaban, rivaroxaban, edoxaban). Their ability to bypass the anticoagulant effects stems from a significantly reduced sensitivity for the direct FXa inhibitors due to a decrease in binding affinity determined using molecular dynamics simulations and free energy computation. Furthermore, F174 modification resulted in a partial loss of inhibition by tissue factor pathway inhibitor, enhancing the procoagulant effect of F174-substituted FX. Consequently, the F174A- and F174S-substituted FX variants effectively counteracted the effects of 2 widely used anticoagulants, apixaban and rivaroxaban, in plasma of atrial fibrillation and venous thromboembolism patients., Conclusion: These human FX variants have the potential to serve as a rescue reversal strategy to overcome the effect of direct FXa inhibitors in case of life-threatening bleeding events or emergency surgical interventions., Competing Interests: Declaration of competing interests P.H.R. and D. Verhoef own equity in VarmX B.V. T.M.H. and S.T. own equity in Coagulation Profile B.V. M.H.A.B. has received consultancy fees from VarmX B.V. (all fees to the institution) and is inventor on intellectual property related to this work. The remaining authors declare no competing financial interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

39. Cancer-associated thrombosis: How many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial?

Author: Petit B, Soudet S, Poenou G, Zarrat E, Accassat S, Plaisance L, Helfer H, Mismetti V, Hello CL, Sevestre MA, Mahé I, and Bertoletti L
Subjects: Humans, Female, Male, Aged, Retrospective Studies, Middle Aged, Administration, Oral, Aged, 80 and over, Patient Selection, Neoplasms complications, Thrombosis etiology, Thrombosis epidemiology, Anticoagulants therapeutic use, Anticoagulants administration & dosage, Randomized Controlled Trials as Topic statistics & numerical data
Abstract: Based on the results of randomized clinical trials (RCT) assessing direct oral anticoagulants (DOACs) for the treatment of patients with cancer-associated thrombosis (CAT), DOACs have been proposed as alternative to low molecular weight heparin by several international guidelines. However, the proportion of CAT patients who would have not been eligible for such trials is currently unknown. Our primary aim was to assess the proportion of patients seen in clinical practice for acute CAT who would not have been eligible for CARAVAGGIO or HOKUSAI-VTE RCT. Secondary aim was to describe patients outcomes according to eligibility. In a multicenter, observational study, all patients consecutively admitted from January 2017 to December 2019 for an acute CAT event were retrospectively analyzed. Patients were classified according to the presence or absence of non-inclusion criteria for CARAVAGGIO or HOKUSAI-VTE RCT. Event free survival during a 6-month follow-up were analyzed as secondary endpoints. Among the 302 patients (women: 53 %, mean age: 67.9 ± 13.2) analyzed, 138 (46 %) for HOKUSAI-VTE cancer and 161 (53 %) for CARAVAGGIO met one or more non-inclusion criteria. Main criteria were upper limb and unsual site thrombosis (n = 63, 18.5 %), anemia/thrombopenia (n = 43, 14.2 %), brain tumors (n = 33, 10.9 %), ECOG PS >2 (n = 28, 9.3 %), severe renal failure (n = 16, 5.3 %). At 6 months, the event-free survival rate was not statistically different between the two groups. Almost half of CAT patients would have not been able to participate to a modern DOAC RCT. Evaluation of DOACs safety and efficacy in this subset of patients deserves further research., Competing Interests: Declaration of Competing Interest No conflicts of interest., (Copyright © 2023 SPLF and Elsevier Masson SAS. All rights reserved.)
Published: 2024
Full Text: View/download PDF

40. Venous thromboembolism in sarcoidosis: Mere comorbidity or catalyst for disease evolution?

Author: Jevnikar M, Poenou G, Montani D, and Bertoletti L
Subjects: Humans, Female, Male, Disease Progression, Middle Aged, Risk Factors, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology, Sarcoidosis epidemiology, Sarcoidosis complications, Sarcoidosis diagnosis, Comorbidity
Abstract: Competing Interests: Declaration of Competing Interest MJ declares Consulting fees for Janssen.GP declares Grants for Leo pharma; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for BMS and Pfizer; Support for attending meetings and/or travel for Pfizer, Viatris and MB.LB declares Grants for MSD and Bayer; Consulting fees for MSD; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for BMS, Pfizer, Viatris, Leo-Pharma and MSD; Support for attending meetings and/or travel for Pfizer, Viatris, BMS and Leo-Pharma.DM declares Grants for Acceleron, Janssen, Merck MSD; Consulting fees for Acceleron, Merck MSD and Janssen; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Bayer, Janssen, Boerhinger, Chiesi, GSK, Ferrer and Merck MSD.
Published: 2024
Full Text: View/download PDF

41. Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer.

Author: Bertoletti L, Lafaie L, LeConte T, Desage AL, Petit B, Ozturk L, Accassat S, Corbaux P, and Poenou G
Subjects: Humans, Neoplasm Recurrence, Local chemically induced, Hemorrhage chemically induced, Anticoagulants, Lung Neoplasms complications, Lung Neoplasms epidemiology, Lung Neoplasms chemically induced, Thrombosis epidemiology, Thrombosis etiology, Pulmonary Embolism
Published: 2024
Full Text: View/download PDF

42. Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry.

Author: Lafaie L, Poenou G, Hanon O, López-Jiménez L, Nieto JA, Lorenzo A, Porras JA, Lumbierres M, Bertoletti L, and Monreal M
Subjects: Female, Humans, Male, Anticoagulants adverse effects, Hemorrhage chemically induced, Hemorrhage epidemiology, Recurrence, Registries, Aged, 80 and over, Observational Studies as Topic, Pulmonary Embolism drug therapy, Venous Thromboembolism drug therapy
Abstract: Background: Age is a major risk factor for venous thromboembolism (VTE), yet patients aged ≥90 years are under-represented in clinical trials of anticoagulant therapy. The objectives were to describe and compare patient clinical characteristics, treatments, and outcomes (VTE recurrence, bleeding, and mortality) during the first 3 months of anticoagulation between VTE patients aged ≥90 years and those aged <90 years., Methods: We analyzed data from the Registro Informatizado Enfermedad TromboEmbὀlica (RIETE), an ongoing global observational registry of patients with objectively confirmed acute VTE., Results: From January 2001 to October 2022, 96,701 patients were registered in RIETE, of whom 3262 (3.4%) were aged ≥90 years. Patients aged ≥90 years were less likely to be men, and to have experienced cancer or recent surgery, but more likely to manifest immobility, chronic heart failure, anemia, renal insufficiency, or dementia than those aged <90 years. Most (99.6%) patients aged ≥90 years were receiving anticoagulant therapy. During the first 3 months, 26 patients aged ≥90 years developed VTE recurrences, 116 experienced major bleeding, and 564 died. Among patients initially presenting with pulmonary embolism (PE), deaths due to PE exceeded those due to fatal bleeding (76 vs. 19). Among those initially presenting with isolated deep-vein thrombosis (DVT), it was the reverse (2 vs. 11 deaths)., Conclusions: In patients aged ≥90 years, the difference in the outcome of anticoagulant treatment depending on the initial presentation of VTE could suggest a need for different management approaches. Clinical trials evaluating the optimal duration of anticoagulation according to initial VTE presentation are warranted to limit excess deaths in this particular population., (© 2023 The American Geriatrics Society.)
Published: 2024
Full Text: View/download PDF

43. Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?

Author: Poenou G, Heestermans M, Lafaie L, Accassat S, Moulin N, Rodière A, Petit B, Duvillard C, Mismetti P, and Bertoletti L
Subjects: Humans, Factor XI therapeutic use, Anticoagulants adverse effects, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Thrombosis drug therapy, Neoplasms complications, Neoplasms drug therapy, Neoplasms chemically induced
Abstract: Direct oral anticoagulants against activated factor X and thrombin were the last milestone in thrombosis treatment. Step by step, they replaced antivitamin K and heparins in most of their therapeutic indications. As effective as the previous anticoagulant, the decreased but persistent risk of bleeding while using direct oral anticoagulants has created space for new therapeutics aiming to provide the same efficacy with better safety. On this basis, drug targeting factor XI emerged as an option. In particular, cancer patients might be one of the populations that will most benefit from this technical advance. In this review, after a brief presentation of the different factor IX inhibitors, we explore the potential benefit of this new treatment for cancer patients.
Published: 2023
Full Text: View/download PDF

44. Temporary inferior vena cava filters factors associated with non-removal.

Author: Dehbi S, Grange R, Poenou G, Ayoub E, Boutet C, Barral FG, Bertoletti L, and Grange S
Subjects: Humans, Treatment Outcome, Retrospective Studies, Device Removal, Vena Cava, Inferior surgery, Vena Cava Filters adverse effects, Venous Thrombosis etiology, Pulmonary Embolism complications, Neoplasms complications
Abstract: Objectives: Inferior vena cava filter (IVCF) placement is indicated when there is a deep vein thrombosis and/or a pulmonary embolism and a contraindication of anticoagulation. Due to the increased risk of recurrent deep venous thrombosis when left in place, IVCF removal is indicated once anticoagulant treatment can be reintroduced. However, many temporary IVCF are not removed. We aimed to analyze the removal rate and predictors of filter non-removal in a university hospital setting., Methods: We collected all the data of consecutive patients who had a retrievable IVCF inserted at the Saint-Etienne University Hospital (France) between April 2012 and November 2019. Rates of filter removal were calculated. We analyzed patient characteristics to assess factors associated with filter non-removal, particularly in patients without a definitive filter indication. The exclusion of this last category of patients allowed us to calculate an adjusted removal rate., Results: The overall removal rate of IVCF was 40.5% (IC 95% 35.6-45.6), and the adjusted removal rate was 62.9 % (IC 95% 56.6-69.2%). No major complications were noted. Advanced age (p < 0.0001) and cancer presence (p < 0.003) were statistically significant predictors of patients not being requested to make a removal attempt., Conclusions: Although most of the filters placed are for therapeutic indications validated by scientific societies, the removal rate in this setting remains suboptimal. The major factors influencing IVCF removal rate are advanced age and cancer presence., Key Points: • Most vena cava filters are placed for therapeutic indications validated by scientific societies. • Vena cava filter removal rates in this setting remain suboptimal. • Major factors influencing IVCF removal rate are advanced age and cancer presence., (© 2022. The Author(s), under exclusive licence to European Society of Radiology.)
Published: 2023
Full Text: View/download PDF

45. Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin.

Author: Tan S, Goudot G, Arnoux A, Tran Y, Maissoro H, Poenou G, Detriche G, Khider L, Mohamedi N, Mirault T, Galloula A, and Messas E
Subjects: Humans, Prospective Studies, Treatment Outcome, Lower Extremity blood supply, Risk Factors, Diabetes Mellitus, Type 2 complications, Metformin, Peripheral Arterial Disease
Abstract: Backgrounds: Patients with type 2 diabetes mellitus (T2DM) are particularly at risk of developing major adverse cardiovascular events (MACE) and peripheral artery disease (PAD) due to an acceleration of the atherosclerotic process linked to hyperglycemia and inflammation with a greater risk of local complications. We aimed to identify the predictive factors for major adverse limb events (MALE) in T2DM patients with PAD to manage modifiable factors at an early stage., Methods: This is a prospective study in which T2DM patients with PAD were included from November 2017 to May 2018 and followed over 12 months. The predictive factors for the onset of MALE, MACE, and death from all causes have been identified., Results: A total of 100 patients were included; 37% of the patients developed a MALE. After multivariate analysis, metformin was associated with a decrease of MALE (odds ratio (OR) = 0.26; 95% confidence interval (CI) [0.10; 0.68]; P = 0.007), and a history of the treatment of intravenous iloprost was associated with an increased risk of MALE (OR = 5.70; 95% CI [1.31; 31.93]; P = 0.029). Regular physical activity was associated with a decreased risk of MACE (OR = 0.07; 95% CI [0; 0.44]; P = 0.021). A history of stroke and a history of venous thromboembolism were associated with an increased all-cause mortality risk with OR = 3.68; 95% CI [1.17; 11.5]; P = 0.025 and OR = 3.78; 95% CI [1.16; 12.3]; P = 0.027., Conclusions: Metformin is protective against local complications in people with diabetes with PAD and should be prescribed to diabetic patients with PAD at an early stage., (Copyright © 2022 Elsevier Inc. All rights reserved.)
Published: 2023
Full Text: View/download PDF

46. Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases.

Author: Heestermans M, Poenou G, Duchez AC, Hamzeh-Cognasse H, Bertoletti L, and Cognasse F
Subjects: Humans, Blood Platelets, Thromboinflammation, Blood Coagulation, Anticoagulants pharmacology, Anticoagulants therapeutic use, Venous Thromboembolism, Venous Thrombosis
Abstract: Venous thromboembolism (VTE) is the third leading cardiovascular cause of death and is conventionally treated with anticoagulants that directly antagonize coagulation. However, recent data have demonstrated that also platelets play a crucial role in VTE pathophysiology. In the current review, we outline how platelets are involved during all stages of experimental venous thrombosis. Platelets mediate initiation of the disease by attaching to the vessel wall upon which they mediate leukocyte recruitment. This process is referred to as immunothrombosis, and within this novel concept inflammatory cells such as leukocytes and platelets directly drive the progression of VTE. In addition to their involvement in immunothrombosis, activated platelets can directly drive venous thrombosis by supporting coagulation and secreting procoagulant factors. Furthermore, fibrinolysis and vessel resolution are (partly) mediated by platelets. Finally, we summarize how conventional antiplatelet therapy can prevent experimental venous thrombosis and impacts (recurrent) VTE in humans.
Published: 2022
Full Text: View/download PDF

47. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications.

Author: Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, and Bertoletti L
Subjects: Humans, Heparin pharmacology, Heparin therapeutic use, Blood Coagulation, Anticoagulants pharmacology, Anticoagulants therapeutic use, Venous Thromboembolism drug therapy
Abstract: Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent) venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a century, and, nowadays, physicians possess a broad panel of multiple anticoagulants to meet the individual needs of a patient. Within this review, we aimed to revise the history of the different anticoagulants that are currently prescribed in the clinic. In addition, we compared their pharmacological properties, medical indications, and the difficulties in implementing new anticoagulants in vulnerable patient populations. Since the introduction of unfractionated heparin in the 1930s, major advances in the mechanistic understanding and the medical use of anticoagulants have allowed for significant improvements to treat VTE patients. However, a new generation of anticoagulants is currently being tested in clinical trials, with the goal of further optimizing medical care., Competing Interests: The authors declare no conflicts of interest.
Published: 2022
Full Text: View/download PDF

48. Pulmonary Embolism in the Cancer Associated Thrombosis Landscape.

Author: Poenou G, Dumitru Dumitru T, Lafaie L, Mismetti V, Ayoub E, Duvillard C, Accassat S, Mismetti P, Heestermans M, and Bertoletti L
Abstract: In cancer patients, pulmonary embolism (PE) is the second leading cause of death after the cancer itself, most likely because of difficulties in diagnosing the disease due to its nonclassical presentation. The risk of PE recurrence and possibly the case-fatality rate depends on whether the patient presents a symptomatic PE, an unsuspected PE, a subsegmental PE, or a catheter-related PE. Choosing the best therapeutic option is challenging and should consider the risk of both the recurrence of thrombosis and the occurrence of bleeding. The purpose of this review is to provide an overview of the clinical characteristics and the treatment of cancer-associated PE, which could benefit clinicians to better manage the deadliest form of thrombosis associated with cancer. After a brief presentation of the epidemiological data, we will present the current attitude towards the diagnosis and the management of cancer patients with PE. Finally, we will discuss the perspectives of how the medical community can improve the management of this severe medical condition.
Published: 2022
Full Text: View/download PDF

49. Cardiac Biomarkers in Patients with Acute Pulmonary Embolism.

Author: Janisset L, Castan M, Poenou G, Lachand R, Mismetti P, Viallon A, and Bertoletti L
Subjects: Acute Disease, Biomarkers, Humans, Prognosis, Risk Assessment methods, Troponin, Natriuretic Peptide, Brain, Pulmonary Embolism complications, Pulmonary Embolism diagnosis
Abstract: Pulmonary embolism is a frequent and potentially fatal disease. The major challenge of initial management lies in prognostic stratification. Since 2014, the European recommendations on the diagnosis and management of acute pulmonary embolism are based on assessing the risk stratification regarding hemodynamic status first, then on a combined risk assessment model using a clinical score, an imaging evaluation of right heart size and the concentration of a serum cardiac biomarker. Usual biomarkers cover cardiac ischemia (troponin and derivates) and dilatation (BNP and derivates). The aim of this review is to offer a practical update on the role of the Troponins and BNPs families of biomarkers and the prognosis of pulmonary embolism, and furthermore, to provide a brief overview of their place in current management.
Published: 2022
Full Text: View/download PDF

50. Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.

Author: Bosquet A, Affo C, Plaisance L, Poenou G, Mortier E, and Mahé I
Subjects: Antimalarials therapeutic use, COVID-19 epidemiology, COVID-19 virology, Drug Repositioning, France epidemiology, Hospitalization statistics & numerical data, Humans, Prescriptions statistics & numerical data, SARS-CoV-2 drug effects, SARS-CoV-2 pathogenicity, Treatment Outcome, Antiviral Agents therapeutic use, Hospitalists psychology, Hydroxychloroquine therapeutic use, Off-Label Use statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, COVID-19 Drug Treatment
Abstract: Introduction: During the first wave of the coronavirus-disease 2019 (covid-19) pandemic in early 2020, hydroxychloroquine (HCQ) was widely prescribed in light of in vitro activity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Our objective was to evaluate in early 2020 the rate of French hospitalists declaring having prescribed HCQ to treat covid-19 patients outside any therapeutic trial, compare the reasons and the determinants for having prescribed HCQ or not., Material and Methods: A national inquiry submitted by email from May 7 to 25, 2020, to a sample of French hospitalists: doctors managing patients hospitalized for covid-19 in a French department of internal medicine or infectious diseases and identified in the directories of French hospitals or as a member of the French Infectious Diseases Society (SPILF). Primary outcome was the percentage of hospitalists declaring having prescribed HCQ to covid-19 patients. Secondary outcomes were reasons and determinants of HCQ prescription., Results: Among 400 (22.8%) responding hospitalists, 45.3% (95% CI, 40.4 to 50.1%) declared having prescribed HCQ to covid-19 patients. Two main profiles were discerned: HCQ prescribers who did not raise its efficacy as a motive, and non-prescribers who based their decision on evidence-based medicine. Multivariate analysis retained the following prescription determinants (adjusted odds ratio; 95% confidence interval): a departmental procedure for HCQ prescription (8.25; 4.79 to 14.20), having prescribed other treatments outside a therapeutic trial (3.21; 1.81 to 5.71), prior HCQ prescription (2.75; 1.5 to 5.03) and HCQ prescribed within the framework of a therapeutic trial (0.56; 0.33 to 0.95)., Conclusion: Almost half of the hospitalists prescribed HCQ. The physician's personality (questioning or not evidence-based-medicine principles in the context of the pandemic) and departmental therapeutic procedures were the main factors influencing HCQ prescription. Establishment of "therapeutic" procedures represents a potential means to improve the quality of therapeutic decision-making during a pandemic., Competing Interests: Dr. Mahé reports grants from BMS Pfizer, grants from LEO Pharma, personal fees and non-financial support from BMS Pfizer, personal fees and non-financial support from Leo Pharma, personal fees and non-financial support from Bayer, outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Published: 2022
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

76 results on '"Poenou G"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources